<SEC-DOCUMENT>0001104659-22-082802.txt : 20220726
<SEC-HEADER>0001104659-22-082802.hdr.sgml : 20220726
<ACCEPTANCE-DATETIME>20220726163104
ACCESSION NUMBER:		0001104659-22-082802
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220722
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220726
DATE AS OF CHANGE:		20220726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		221107458

	BUSINESS ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105
		BUSINESS PHONE:		(781) 788-8869

	MAIL ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2221834d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20220722">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_KPRX_eyegatepharma.com_20220722 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20220722_20220722 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001372514 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityCentralIndexKey">0001372514</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kprx-20220722.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-22to2022-07-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-22</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_900_edei--DocumentType_c20220722__20220722_zURgnU8GldA7"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO SECTION&#160;13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_90E_edei--DocumentPeriodEndDate_c20220722__20220722_zxox4ERayTz5"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 22, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--EntityRegistrantName_c20220722__20220722_zcxxobyR3CU4" style="font-size: 14pt"><b><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityRegistrantName">KIORA
PHARMACEUTICALS, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20220722__20220722_zoeUWDM23LSk"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><b><span id="xdx_90D_edei--EntityFileNumber_c20220722__20220722_zFPspGw88nD9"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityFileNumber">001-36672</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20220722__20220722_zzUE1arMF25i"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityTaxIdentificationNumber">98-0443284</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20220722__20220722_zr5jTWhBfxpj"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressAddressLine1">1371 East 2100 South</ix:nonNumeric></span></b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine2_c20220722__20220722_zaLL9F6KnP6c"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20220722__20220722_zVLpbUQYYvDk"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressCityOrTown">Salt Lake City</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20220722__20220722_zTnmJ6gRSSUb"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20220722__20220722_zo2nctXr1OZa"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b>&#160;</b></p>
</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20220722__20220722_z0G2koUmlAj5"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b></p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20220722__20220722_zhF9ftfNk2bl"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_908_edei--LocalPhoneNumber_c20220722__20220722_zsqMfwz2ITU5"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:LocalPhoneNumber">788-9043</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20220722__20220722_zy0SB7EsS2wk"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Written communications pursuant to Rule&#160;425
under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20220722__20220722_znjKy5ItB1Qk"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementTenderOffer_c20220722__20220722_zoUoJMfy0gd6"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20220722__20220722_zItCbTSfkJo9"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class:</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 23%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20220722__20220722_zDFcqT7u58y1"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:Security12bTitle">Common Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--TradingSymbol_c20220722__20220722_z6BA1n6RWsGf"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" name="dei:TradingSymbol">KPRX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_907_edei--SecurityExchangeName_c20220722__20220722_zdkSWghatbuf"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20220722__20220722_z368CkjiE9ec"><ix:nonNumeric contextRef="From2022-07-22to2022-07-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 1.01 Entry into
a Material Definitive Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&#160;22, 2022,
Kiora Pharmaceuticals,&#160;Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an Underwriting Agreement (the &#8220;Underwriting
Agreement&#8221;) with Ladenburg Thalmann&#160;&amp; Co. Inc., as underwriter (the &#8220;Underwriter&#8221;), pursuant to which the Company
agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the &#8220;Public Offering&#8221;), (i)&#160;19,770,172
shares of common stock (the &#8220;Common Shares&#8221;), (ii)&#160;1,280 shares of Series&#160;E Convertible Preferred Stock (the &#8220;Preferred
Shares&#8221;) convertible into up to 6,400,000 shares of common stock, (iii)&#160;Class&#160;A Warrants (the &#8220;Class&#160;A Warrants&#8221;)
to purchase up to 26,170,172 shares of common stock, and (iv)&#160;Class&#160;B Warrants (the &#8220;Class&#160;B Warrants&#8221; and,
together with the Class&#160;A Warrants, the &#8220;Warrants&#8221;), priced at a public offering price of $0.20 per Common Shares, Class&#160;A
Warrants and Class&#160;B Warrants or $1,000 per Preferred Share, 5,000 Class&#160;A Warrants and 5,000 Class&#160;B Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 45-day option (the &#8220;Overallotment Option&#8221;) to purchase
up to (i)&#160;3,925,525 additional Common Shares, (ii)&#160;3,925,525 additional Class&#160;A Warrants and/or (ii)&#160;3,925,525 additional
Class&#160;B Warrants, solely to cover over-allotments. The Underwriter fully exercised the Overallotment Option on July&#160;25, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The securities were offered
by the Company pursuant to the Registration Statement on Form&#160;S-1 (File No.&#160;333-264641), which was initially filed with the
Securities and Exchange Commission (the &#8220;Commission&#8221;) on May&#160;3, 2022, amended on July&#160;13, 2022, July&#160;19, 2022
and July&#160;21, 2022, and declared effective by the Commission on July&#160;21, 2022 (the &#8220;Registration Statement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&#160;26, 2022,
the Public Offering closed, and the Company issued and sold (i)&#160;23,695,697 Common Shares (including 3,925,525 Common Shares sold
pursuant to the exercise of the Overallotment Option), (ii)&#160;1,280 Preferred Shares, (iii)&#160;30,095,697 Class&#160;A Warrants (including
3,925,525 Class&#160;A Warrants sold pursuant to the exercise of the Overallotment Option), and (iv)&#160;30,095,697 Class&#160;B Warrants
(including 3,925,525 Class&#160;B Warrants sold pursuant to the exercise of the Overallotment Option). The net proceeds to the Company,
after deducting the underwriting discount and commissions and estimated offering expenses payable by the Company, were approximately $5.3
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each Warrant is
exercisable at a price per share of common stock of $0.20.&#160;&#160;Each Warrant will initially be exercisable following approval
by the stockholders of the Company of the exercise of the Warrants and of a reverse stock split that would resulting in sufficient
shares of common stock being available for such exercise. The Class&#160;A Warrants will expire on the one-year anniversary of their
initial exercise date, and the Class&#160;B Warrants will expire on the five-year anniversary of their initial exercise date. The
exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends,
stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock.
Subject to limited exceptions, a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder
(together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such
holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a
holder prior to the issuance of any Warrants, 9.99%) of the shares of common stock then outstanding. At the holder&#8217;s option,
upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the
shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days&#8217; prior notice to the
Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Underwriting Agreement
contains representations, warranties and covenants made by the Company that are customary for transactions of this type. Under the terms
of the Underwriting Agreement, the Company has agreed to indemnify the Underwriter against certain liabilities, including liabilities
under the Securities Act of 1933, as amended. In addition, pursuant to the terms of the Underwriting Agreement, the Company and its executive
officers and directors have entered into lock-up agreements providing that the Company and each of these persons may not, without the
prior written approval of the Underwriter, subject to limited exceptions, offer, sell, transfer or otherwise dispose of the Company&#8217;s
securities for a period of 90 days following the date of the Underwriting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&#160;22, 2022,
the Company entered into a warrant agency agreement with the Company&#8217;s transfer agent, VStock Transfer, LLC, which will also act as
the warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the &#8220;Warrant
Agency Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing summaries
of the Underwriting Agreement, the Class&#160;A Warrants, the Class&#160;B Warrants and the Warrant Agency Agreement do not purport to
be complete and are subject to, and qualified in their entirety by, such documents attached as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively,
to this Current Report on Form&#160;8-K (this &#8220;Current Report&#8221;), which are incorporated herein by reference. The Underwriting
Agreement is attached hereto as an exhibit to provide interested persons with information regarding its terms but is not intended to provide
any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement
were made only for purposes of the Underwriting Agreement as of specific dates indicated therein, were solely for the benefit of the parties
to the Underwriting Agreement and may be subject to limitations agreed upon by the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;5.03. Amendments to Articles of
Incorporation or Bylaws; Change in Fiscal Year.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;22, 2022, the Company filed a Certificate of Designation
of Preferences, Rights and Limitations of Series&#160;E Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) with
the Delaware Secretary of State. Each share of Series&#160;E Convertible Preferred Stock (the &#8220;Series&#160;E Preferred Stock&#8221;)
is convertible into shares of the Company&#8217;s common stock at any time at the holder&#8217;s option. The holder, however, will be
prohibited from converting shares Series&#160;E Preferred Stock into common stock if, as a result of such conversion, the holder, together
with its affiliates, would own more than 4.99% of the shares of the Company&#8217;s shares of common stock then issued and outstanding,
which may be increased to 9.99% in certain circumstances. Shares of Series&#160;E Preferred Stock will generally have no voting rights,
except as required by law and except that the consent of holders of a majority of the outstanding Series&#160;E Preferred Stock will be
required to (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;E Preferred Stock or alter or
amend the Certificate of Designation, (ii)&#160;amend any provision of the Company&#8217;s certificate of incorporation that would have
a materially adverse effect on the rights of the holders of the Series&#160;E Preferred Stock, (iii)&#160;increase the number of authorized
shares of Series&#160;E Preferred Stock, or (iv)&#160;enter into any agreement with respect to the foregoing. Shares of Series&#160;E
Preferred Stock will not be entitled to receive any dividends, unless and until specifically declared by the Company&#8217;s board of
directors, and will rank:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on parity with the Company&#8217;s common stock on an as-converted basis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on&#160;&#160;parity with the Company&#8217;s Series&#160;A Convertible Preferred Stock, Series&#160;B Convertible Preferred Stock, Series&#160;C Convertible Preferred Stock and Series&#160;D Convertible Preferred Stock, none of which is outstanding;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">senior to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms junior to the Series&#160;E Preferred Stock;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on parity to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms on parity with the Series&#160;E Preferred Stock; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">junior to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms senior to the Series&#160;E Preferred Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Certificate of Designation relating to the Series&#160;E
Preferred Stock is filed as Exhibit&#160;3.1 to this Current Report on Form&#160;8-K. The foregoing summary of the terms of the Certificate
of Designation is subject to, and qualified in its entirety by, such document, which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&#160;22, 2022,
the Company issued a press release announcing that it had priced the Public Offering, a copy of which is attached as Exhibit&#160;99.1
to this Current Report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July&#160;26, 2022,
the Company issued a press release announcing the closing of the Public Offering and the full exercise of the Overallotment Option, a
copy of which is attached as Exhibit&#160;99.2 to this Current Report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Information contained
on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report,
and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is as inactive
textual references only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2221834d1_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2221834d1_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement dated as of July&#160;22, 2022, by and between Kiora Pharmaceuticals,&#160;Inc. and Ladenburg Thalmann&#160;&amp; Co. Inc.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2221834d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2221834d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;E Convertible Preferred Stock</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-9.htm">4.1</a></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-9.htm">Form&#160;of Class&#160;A Warrant (incorporated by reference to Exhibit&#160;4.9 of Company&#8217;s Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 filed on July&#160;21, 2022 (File No.&#160;333-264641))</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-10.htm">4.2</a></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-10.htm">Form&#160;of Class&#160;B Warrant (incorporated by reference to Exhibit&#160;4.10 of Company&#8217;s Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 filed on July&#160;21, 2022 (File No.&#160;333-264641))</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2221834d1_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2221834d1_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agency Agreement dated July&#160;22, 2022, by and between Kiora Pharmaceuticals,&#160;Inc. and VStock Transfer, LLC</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2221834d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2221834d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated July&#160;22, 2022</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2221834d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="tm2221834d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated July&#160;26, 2022</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KIORA PHARMACEUTICALS,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July&#160;26, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin: 0pt">&#160;</p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LboO/9ilQ0WcImOIt8VFKW7NSOt0j+Rb2m2IIRCSc74cIUZiSxtdIsNllaWQY1WXyiFkeENGc0XvSHb7GPzM8K6tY2Vcv/7AhDyDnpmNl8rfe2ejLRYxhPOJnE0iCaGMpws4HUTQ6QmZmy7QOK1KUKaAE1PNGp3idviQqzcZqto+6YxsNZkY5Dgc5A9EoYzgSI16ET8spGkiglFfgdgyPesu5mkdVbAusfJZdkD/HXwB4XRJHw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2221834d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>19,770,172 SHARES <FONT STYLE="text-transform: uppercase">of
Common Stock,</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>1,280
SHARES OF SERIES E CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO 6,400,000 SHARES OF COMMON STOCK)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>26,170,172
Class&nbsp;A Warrants (EXERCISABLE FOR 26,170,172 SHARES OF COMMON STOCK) and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>26,170,172
class B Warrants (EXERCISABLE FOR 26,170,172 SHARES OF COMMON STOCK)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>of</B></FONT><B>
KIORA PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 192pt">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">July&nbsp;22, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As the Representative of the</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several underwriters, if any, named in <U>Schedule
I</U> hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">640 Fifth Avenue, 4th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Kiora Pharmaceuticals,&nbsp;Inc.,
a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all
entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Kiora Pharmaceuticals,&nbsp;Inc.,
the &#8220;<U>Company</U>&#8221;), hereby confirms its agreement (this &#8220;<U>Agreement</U>&#8221;) with the several underwriters (such
underwriters, including the Representative (as defined below), the &#8220;<U>Underwriters</U>&#8221; and each an &#8220;<U>Underwriter</U>&#8221;)
named in <U>Schedule I</U> hereto for which Ladenburg Thalmann&nbsp;&amp; Co. Inc. is acting as representative to the several Underwriters
(the &#8220;<U>Representative</U>&#8221; and if there are no Underwriters other than the Representative, references to multiple Underwriters
shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is understood that the
several Underwriters are to make a public offering of the Public Securities as soon as the Representative deems it advisable to do so.
The Public Securities are to be initially offered to the public at the public offering price set forth in the Prospectus. The Representative
may from time to time thereafter change the public offering price and other selling terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is further understood that
you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities and, if any, the Option Securities
in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, (a)&nbsp;capitalized terms that are not otherwise defined herein have the
meanings given to such terms in the Certificate of Designation (as defined below) and (b)&nbsp;the following terms have the meanings set
forth in this Section&nbsp;1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8220;<U>Action</U>&#8221;
shall have the meaning ascribed to such term in Section&nbsp;3.1(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Affiliate</U>&#8221;
means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled
by or is under common control with such Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Amendment</U>&#8221;
means the amendment to the Company&#8217;s certificate of incorporation that effects a reverse stock split such that, following such reverse
stock split, there are authorized and unissued shares of Common Stock sufficient for the issuance of the Warrant Shares upon the exercise
of any purchase rights under the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Authorized
Share Approval</U>&#8221; means approval of the Amendment by the shareholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Authorized
Share Increase Date</U>&#8221; means, subject to Authorized Share Approval, the date on which the Amendment is filed and accepted with
the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Board
of Directors</U>&#8221; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Business
Day</U>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Certificate
of Designation</U>&#8221; means the Certificate of Designation to be filed prior to the Closing by the Company with the Secretary of State
of Delaware in the form of <U>Exhibit&nbsp;A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Class&nbsp;A
Warrant Shares</U>&#8221; means the shares of Common Stock issuable upon exercise of the Class&nbsp;A Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Class&nbsp;A
Warrants</U>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with
Section&nbsp;2.1(a)(iii)&nbsp;and Section&nbsp;2.2, which Class&nbsp;A Warrants shall be exercisable at any time on or after the
later of (i)&nbsp;the Authorized Share Increase Date and (ii)&nbsp;the date Shareholder Approval is received and effective and have
a term of exercise equal to one (1)&nbsp;year, in the form of <U>Exhibit&nbsp;F</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Class&nbsp;B
Warrant Shares</U>&#8221; means the shares of Common Stock issuable upon exercise of the Class&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Class&nbsp;B
Warrants</U>&#8221; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with Section&nbsp;2.1(a)(iv)&nbsp;and
Section&nbsp;2.2, which Class&nbsp;B Warrants shall be exercisable at any time on or after the later of (i)&nbsp;the Authorized Share
Increase Date and (ii)&nbsp;the date Shareholder Approval is received and effective and have a term of exercise equal to five (5)&nbsp;years,
in the form of <U>Exhibit&nbsp;G</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing</U>&#8221;
means the closing of the purchase and sale of the Closing Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Date</U>&#8221; means the hour and the date on the Trading Day on which all conditions precedent to (i)&nbsp;the Underwriters&#8217; obligations
to pay the Closing Purchase Price and (ii)&nbsp;the Company&#8217;s obligations to deliver the Closing Securities, in each case, have
been satisfied or waived, but in no event later than 10:00 a.m.&nbsp;(New York City time) on the second (2<SUP>nd</SUP>) Trading Day following
the date hereof or at such earlier time as shall be agreed upon by the Representative and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Preferred Shares</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(b), which aggregate purchase price shall be
net of the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Securities</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Shares</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Closing
Warrants</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Combined
Preferred Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Combined
Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Commission</U>&#8221;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Common
Stock</U>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Common
Stock Equivalents</U>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Company
Auditor</U>&#8221; means EisnerAmper LLP, with offices located at 733 Third Avenue, New York, NY 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Company
Counsel</U>&#8221; means Burns&nbsp;&amp; Levinson, LLP, with offices located at 125 High Street, Boston, MA 02110.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Price</U>&#8221; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Shares</U>&#8221; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Effective
Date</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>EGS</U>&#8221;
means Ellenoff Grossman&nbsp;&amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Exchange
Act</U>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Execution
Date</U>&#8221; shall mean the date on which the parties execute and enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Exempt
Issuance</U>&#8221; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
(b)&nbsp;securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities or to extend the term of such securities, and (c)&nbsp;securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that
such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule&nbsp;144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.20(a)&nbsp;herein,
and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>FCPA</U>&#8221;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>FINRA</U>&#8221;
means the Financial Industry Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>GAAP</U>&#8221;
shall have the meaning ascribed to such term in Section&nbsp;3.1(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Indebtedness</U>&#8221;
means (a)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
the ordinary course of business), (b)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except
guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (c)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with
GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Liens</U>&#8221;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Lock-Up
Agreements</U>&#8221; means the lock-up agreements that are delivered on the date hereof by each of the Company&#8217;s officers and directors,
in the form of <U>Exhibit&nbsp;D</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Material
Adverse Effect</U>&#8221; means (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii)&nbsp;a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of
the Company and the Subsidiaries, taken as a whole or (iii)&nbsp;a material adverse effect on the Company&#8217;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Offering</U>&#8221;
shall have the meaning ascribed to such term in Section&nbsp;2.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option</U>&#8221;
shall have the meaning ascribed to such term in Section&nbsp;2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option
Closing Date</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option
Closing Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.2(b), which aggregate purchase price
shall be net of the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option
Securities</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option
Shares</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Option
Warrants</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Person</U>&#8221;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Preferred
Stock</U>&#8221; means up to 1,280 shares of the Company&#8217;s Series&nbsp;E Convertible Preferred Stock issued or issuable pursuant
to Section&nbsp;2.1(a)(ii)&nbsp;and having the rights, preferences and privileges set forth in the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Preferred
Stock Agency Agreement</U>&#8221; means the addendum to the Company&#8217;s Transfer Agency and Registrar Services Agreement with the
Transfer Agent, pursuant to which the Transfer Agent agrees to act as transfer agent and conversion agent for the Preferred Stock, in
the form of <U>Exhibit&nbsp;H </U>attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Preliminary
Prospectus</U>&#8221; means, if any, any preliminary prospectus relating to the Securities included in the Registration Statement or filed
with the Commission pursuant to Rule&nbsp;424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Proceeding</U>&#8221;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Prospectus</U>&#8221;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Prospectus
Supplement</U>&#8221; means, if any, any supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that
is filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Public
Securities</U>&#8221; means, collectively, the Closing Securities and, if any, the Option Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Registration
Statement</U>&#8221; means, collectively, the various parts of the registration statement prepared by the Company on Form&nbsp;S-1 (File
No.&nbsp;333-264641) with respect to the Securities, each as amended as of the date hereof, including the Prospectus and Prospectus Supplement,
if any, the Preliminary Prospectus, if any, and all exhibits filed with or incorporated by reference into such registration statement,
and includes any Rule&nbsp;462(b)&nbsp;Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Required
Approvals</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Rule&nbsp;424</U>&#8221;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U>&#8221; means any registration statement prepared by the Company registering additional Public Securities, which was filed
with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule&nbsp;462(b)&nbsp;promulgated by
the Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>SEC Reports</U>&#8221;
shall have the meaning ascribed to such term in Section&nbsp;3.1(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Securities</U>&#8221;
means the Closing Securities, the Option Securities and the Underlying Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Securities
Act</U>&#8221; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Share
Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Shareholder
Approval</U>&#8221; means such approval as may be required by the applicable rules&nbsp;and regulations of the Nasdaq Capital Market (or
any successor entity) from the shareholders of the Company to permit the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Shares</U>&#8221;
means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section&nbsp;2.1(a)(i)&nbsp;and Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Subsidiary</U>&#8221;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Day</U>&#8221; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Market</U>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Transaction
Documents</U>&#8221; means this Agreement, the Certificate of Designation, the Warrants, the Warrant Agency Agreement, the Preferred Stock
Agency Agreement, the Lock-Up Agreements and any other documents or agreements executed in connection with the transactions contemplated
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Transfer
Agent</U>&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, with offices located at 18 Lafayette Place, Woodmere,
New York 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Underlying
Shares</U>&#8221; means, collectively, the Conversion Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Warrant
Agency Agreement</U>&#8221; means the warrant agency agreement dated on or about the Closing Date, by and between the Company and VStock
Transfer, LLC in the form of <U>Exhibit&nbsp;E</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Warrant
Purchase Price</U>&#8221; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Warrant
Shares</U>&#8221; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Warrants</U>&#8221;
means, collectively, the Class&nbsp;A Warrants and the Class&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate 19,770,172 shares of Common Stock,
1,280 shares of Preferred Stock, 26,170,172 Class&nbsp;A Warrants and 26,170,172 Class&nbsp;B Warrants, and each Underwriter agrees to
purchase, severally and not jointly, at the Closing, the following securities of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
number of shares of Common Stock (the &#8220;<U>Closing Shares</U>&#8221;) set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
number of shares of Preferred Stock (the &#8220;<U>Closing Preferred Shares</U>&#8221;) set forth opposite the name of such Underwriter
on <U>Schedule I</U> hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;A
Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof
(the &#8220;<U>Closing Class&nbsp;A Warrants</U>&#8221;), which Class&nbsp;A Warrants shall have an exercise price of $0.20, subject to
adjustment as provided therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;B
Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof
(the &#8220;<U>Closing Class&nbsp;B Warrants</U>&#8221;, collectively with the Closing Class&nbsp;A Warrants, the &#8220;<U>Closing Warrants</U>&#8221;
and, collectively with the Closing Shares and Closing Preferred Shares, the &#8220;<U>Closing Securities</U>&#8221;), which Class&nbsp;B
Warrants shall have an exercise price of $0.20, subject to adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereto (the &#8220;<U>Closing Purchase Price</U>&#8221;). The combined purchase price for one Share, one Class&nbsp;A Warrant to
purchase one Warrant Share and one Class&nbsp;B Warrant to purchase one Warrant Share shall be $0.184 (the &#8220;<U>Combined Purchase
Price</U>&#8221;) (for the avoidance of doubt, solely with respect to any Closing Securities sold to certain investors introduced by the
Company included in Exhibit&nbsp;B to the Engagement Agreement (as defined herein in Section&nbsp;7.2), the Combined Purchase Price shall
be $0.19) which shall be allocated as $0.1656 per Share (the &#8220;<U>Share Purchase Price</U>&#8221;), $0.0092 per Class&nbsp;A Warrant
and $0.0092 per Class&nbsp;B Warrant (the &#8220;<U>Warrant Purchase Price</U>&#8221;). The combined purchase price for one Closing Preferred
Share, one Class&nbsp;A Warrant to purchase 5,000 Warrant Shares and one Class&nbsp;B Warrant to purchase 5,000 Warrant Shares shall be
$920.00 (the &#8220;<U>Combined Preferred Purchase Price</U>&#8221;) which shall be allocated as $828.00 per Preferred Share, $46.00 per
Class&nbsp;A Warrant and $46.00 per Class&nbsp;B Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available funds
equal to such Underwriter&#8217;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its respective
Closing Securities and the Company shall deliver the other items required pursuant to Section&nbsp;2.3 deliverable at the Closing. Upon
satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of EGS or such
other location as the Company and Representative shall mutually agree. The Public Securities are to be offered initially to the public
at the offering price set forth on the cover page&nbsp;of the Prospectus (the &#8220;<U>Offering</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that, with respect to any Notice(s)&nbsp;of Conversion (as defined in the Certificate of Designation)
delivered by a Holder (as defined in the Certificate of Designation) on or prior to 12:00 p.m.&nbsp;(New York City time) on the Closing
Date, which Notice(s)&nbsp;of Conversion may be delivered at any time after the time of execution of this Agreement, the Company shall
deliver the Conversion Shares (as defined in the Certificate of Designation) subject to such notice(s)&nbsp;to the Holder by 4:00 p.m.&nbsp;(New
York City time) on the Closing Date and the Closing Date shall be the Share Delivery Date (as defined in the Certificate of Designation)
under the Certificate of Designation. The Company acknowledges and agrees that the Holders are third-party beneficiaries of this covenant
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
to Purchase Additional Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative
is hereby granted an option (the &#8220;<U>Option</U>&#8221;) to purchase, in the aggregate, up to 3,925,525 shares of Common Stock (the
 &#8220;<U>Option Shares</U>&#8221;), Class&nbsp;A Warrants to purchase up to 3,925,525 shares of Common Stock and Class&nbsp;B Warrants
to purchase up to 3,925,525 shares of Common Stock (the &#8220;<U>Option Warrants</U>&#8221; and, collectively with the Option Shares,
the &#8220;<U>Option Securities</U>&#8221;) which may be purchased in any combination of Option Shares and/or Option Warrants at the Share
Purchase Price and/or Warrant Purchase Price, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with an exercise of the Option, (a)&nbsp;the purchase price to be paid for the Option Shares is equal to the product of the
Share Purchase Price multiplied by the number of Option Shares to be purchased and (b)&nbsp;the purchase price to be paid for the Option
Warrants is equal to the product of the Warrant Purchase Price multiplied by the number of Option Warrants to be purchased (the aggregate
purchase price to be paid on an Option Closing Date, the &#8220;<U>Option Closing Purchase Price</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Option granted pursuant to this Section&nbsp;2.2 may be exercised by the Representative as to all (at any time) or any part (from
time to time) of the Option Securities within forty-five (45) days after the Execution Date. An Underwriter will not be under any
obligation to purchase any Option Securities prior to the exercise of the Option by the Representative. Option granted hereby may be
exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail
or electronic transmission setting forth the number of Option Shares and/or Option Warrants to be purchased and the date and time
for delivery of and payment for the Option Securities (each, an &#8220;<U>Option Closing Date</U>&#8221;), which will not be later
than two (2)&nbsp;full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the
Representative, at the offices of EGS or at such other place (including remotely by other electronic transmission) as shall be
agreed upon by the Company and the Representative. If such delivery and payment for the Option Securities does not occur on the
Closing Date, each Option Closing Date will be as set forth in the notice. Upon exercise of the Option, the Company will become
obligated to convey to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will become
obligated to purchase, the number of Option Shares and/or Option Warrants specified in such notice. The Representative may cancel
the Option at any time prior to the expiration of the Option by written notice to the Company. On each Option Closing Date, if any,
each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available funds equal to such
Underwriter&#8217;s Option Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its
respective Option Securities and the Company shall deliver the other items required pursuant to Section&nbsp;2.3 deliverable at the
Option Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Option Closing shall occur
at the offices of EGS or such other location as the Company and Representative shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.
The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shares shall be
delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Closing Preferred Shares, which shares shall be delivered via The Depository Trust Company Deposit or Withdrawal
at Custodian system for the accounts of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Closing Class&nbsp;A Warrants and, as to each Option Closing Date, if any, the applicable Option Warrants via The
Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Closing Class&nbsp;B Warrants and, as to each Option Closing Date, if any, the applicable Option Warrants via The
Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Warrant Agency Agreement duly executed by the parties thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, the Preferred Stock Agency Agreement duly executed by the parties thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of the State of
Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance
letter, substantially in the form of <U>Exhibit&nbsp;I</U> attached hereto and as to the Closing Date and as to each Option Closing Date,
if any, a bring-down opinion including, without limitation, a negative assurance letter from Company Counsel in form and substance reasonably
satisfactory to the Representative and the favorable opinions of intellectual property legal counsel and regulatory legal counsel to the
Company, including, without limitation, a negative assurance letter, addressed to the Underwriters and in form and substance satisfactory
to the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contemporaneously
herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all respects to the
Representative from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down letter dated as of
the Closing Date and each Option Closing Date, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date and on each Option Closing Date, the duly executed and delivered Officer&#8217;s Certificate, substantially in the form
required by <U>Exhibit&nbsp;B</U> attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing Date and on each Option Closing Date, the duly executed and delivered Secretary&#8217;s Certificate, substantially in the
form required by <U>Exhibit&nbsp;C</U> attached hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contemporaneously
herewith, the duly executed and delivered Lock-Up Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option Closing Date are
subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company already
qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the Company contained
herein (unless as of a specific date therein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been performed
in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section&nbsp;2.3 of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Registration Statement shall be effective on the date of this Agreement and at each of the Closing Date and each Option Closing Date,
if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose
shall have been instituted or shall, to the Company&#8217;s knowledge be pending or contemplated by the Commission and any request on
the part of the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation allowable
or payable to the Underwriters as described in the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Closing Shares, the Option Shares and the Underlying Shares have been approved for listing on the Trading Market; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior
to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have been no material adverse change
or development involving a prospective material adverse change in the condition or prospects or the business activities, financial
or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement and
Prospectus; (ii)&nbsp;no action suit or proceeding, at law or in equity, shall have been pending or threatened against the Company
or any Affiliate of the Company before or by any court or federal or state commission, board or other administrative agency wherein
an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial
condition or income of the Company, except as set forth in the Registration Statement and Prospectus; (iii)&nbsp;no stop order shall
have been issued under the Securities Act with respect to the Registration Statement and no proceedings therefor shall have been
initiated or threatened by the Commission; and (iv)&nbsp;the Registration Statement and the Prospectus and any amendments or
supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities
Act and the rules&nbsp;and regulations thereunder and shall conform in all material respects to the requirements of the Securities
Act and the rules&nbsp;and regulations thereunder, and neither the Registration Statement nor the Prospectus nor any amendment or
supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Execution Date, as of the Closing
Date and as of each Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries or any of them in
the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction
Documents by the Company, the filing of the Certificate of Designation with the Secretary of State of the State of Delaware and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in
connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights
generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the filing of the Certificate of Designation with the Secretary of State of the State of Delaware, the issuance and sale of
the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;conflict with
or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational
or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would
become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or
give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or
any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law,
rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company
or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filing with the Commission
of the Prospectus, (ii)&nbsp;such filings as are required to be made under applicable state securities laws, (iii)&nbsp;Authorized Share
Approval and (iv)&nbsp;Shareholder Approval (collectively, the &#8220;<U>Required Approvals</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Statement</U>. The Company has filed with the Commission the Registration Statement, including any related Prospectus or
Prospectuses, for the registration of the Securities under the Securities Act, which Registration Statement has been prepared by the
Company in all material respects in conformity with the requirements of the Securities Act and the rules&nbsp;and regulations of the
Commission under the Securities Act. The Registration Statement has been declared effective by the Commission on July&nbsp;21, 2022
(the &#8220;<U>Effective Date</U>&#8221;). The Company has advised the Representative of all further information (financial and
other) with respect to the Company required to be set forth therein in the Registration Statement and Prospectus Supplement. Any
reference in this Agreement to the Registration Statement, the Prospectus or the Prospectus Supplement shall be deemed to refer to
and include the documents incorporated by reference therein; and any reference in this Agreement to the terms &#8220;amend,&#8221;
 &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Prospectus or the Prospectus
Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this
Agreement, or the issue date of the Prospectus or the Prospectus Supplement, as the case may be, deemed to be incorporated therein
by reference. All references in this Agreement to financial statements and schedules and other information which is
 &#8220;contained,&#8221; &#8220;included,&#8221; &#8220;described,&#8221; &#8220;referenced,&#8221; &#8220;set forth&#8221; or
 &#8220;stated&#8221; in the Registration Statement, the Prospectus or the Prospectus Supplement (and all other references of like
import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed
to be incorporated by reference in the Registration Statement, the Prospectus or the Prospectus Supplement, as the case may be. No
stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus or the Prospectus Supplement has
been issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company's knowledge, is threatened
by the Commission. For purposes of this Agreement, &#8220;<U>free writing prospectus</U>&#8221; has the meaning set forth in
Rule&nbsp;405 under the Securities Act. The Company will not, without the prior consent of the Representative, prepare, use or refer
to, any free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Securities</U>. The Securities are duly authorized, or in the case of the Warrant Shares, will be on the Authorized Share Increase
Date, and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Underlying Shares, when issued in accordance with the terms
of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The holder of the Securities will not be subject to personal liability by reason of being such holders. The Securities are not and will
not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.
All corporate action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken.
The Securities conform in all material respects to all statements with respect thereto contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth in the SEC Reports. The Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&#8217;s
stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
the capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Underwriters). There are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or
arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The
Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. The authorized shares of the Company conform in all material
respects to all statements relating thereto contained in the Registration Statement and the Prospectus. The offers and sales of the Company&#8217;s
securities were at all relevant times either registered under the Securities Act and the applicable state securities or Blue Sky laws
or, based in part on the representations and warranties of the purchasers, exempt from such registration requirements. Except for the
Authorized Share Approval and Shareholder Approval, no further approval or authorization of any stockholder, the Board of Directors or
others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&#8217;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the &#8220;<U>SEC Reports</U>&#8221;) on a timely basis or has received a valid extension of such time of filing and has
filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all
material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed,
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules&nbsp;and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<U>GAAP</U>&#8221;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. The agreements and documents described
in the Registration Statement, the Prospectus, the Prospectus Supplement and the SEC Reports conform to the descriptions thereof contained
therein and there are no agreements or other documents required by the Securities Act and the rules&nbsp;and regulations thereunder to
be described in the Registration Statement, the Prospectus, the Prospectus Supplement or the SEC Reports or to be filed with the Commission
as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized
or described) to which the Company is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to in the Registration
Statement, the Prospectus, the Prospectus Supplement or the SEC Reports, or (ii)&nbsp;is material to the Company&#8217;s business, has
been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against
the Company and, to the Company&#8217;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally, (y)&nbsp;as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z)&nbsp;that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefore may be brought. None of such agreements or instruments has been assigned by the Company,
and neither the Company nor, to the best of the Company&#8217;s knowledge, any other party is in default thereunder and, to the best of
the Company&#8217;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a
default thereunder. To the best of the Company&#8217;s knowledge, performance by the Company of the material provisions of such agreements
or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental
agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation,
those relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i)&nbsp;there
has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii)&nbsp;the Company has not incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B)&nbsp;liabilities not required to
be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock, (v)&nbsp;the Company has not issued any equity securities to any officer, director or Affiliate, except
pursuant to existing Company stock option plans and (vi)&nbsp;no officer or director of the Company has resigned from any position
with the Company. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or
development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least 1 Trading Day prior to the date that this representation is made. Unless otherwise disclosed in an SEC Report
filed prior to the date hereof, the Company has not: (i)&nbsp;issued any securities or incurred any liability or obligation, direct
or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or in respect to its
capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<U>Action</U>&#8221;)
which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees
is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan
or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in
each case as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each, a &#8220;<U>Material
Permit</U>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit. The disclosures in the Registration Statement concerning the effects of Federal, State, local and all foreign
regulation on the Company&#8217;s business as currently contemplated are correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights to
lease or otherwise use, all real property and all personal property that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)&nbsp;Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP, and
the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in
compliance, except where failure to be in compliance could not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
do so could have a Material Adverse Effect (collectively, the &#8220;<U>Intellectual Property Rights</U>&#8221;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the
rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing
for the borrowing of money from or lending of money to or otherwise requiring payments to or from, any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is
an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary
or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Subject to the material
weaknesses identified in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations,
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization,
and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act
is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules&nbsp;and forms. The
Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<U>Evaluation
Date</U>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Prospectus, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company,
any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. To the Company&#8217;s knowledge, there
are no other arrangements, agreements or understandings of the Company or, to the Company&#8217;s knowledge, any of its stockholders that
may affect the Underwriters&#8217; compensation, as determined by FINRA. The Company has not made any direct or indirect payments (in
cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&#8217;s fee, consulting fee or otherwise, in consideration of such
person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii)&nbsp;
any FINRA member; or (iii)&nbsp;any person or entity that has any direct or indirect affiliation or association with any FINRA member,
within the twelve months prior to the Execution Date. None of the net proceeds of the Offering will be paid by the Company to any participating
FINRA member or its affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities will not be or
be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. Except as disclosed in the SEC Reports, the Company is, and has no reason to believe
that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common
Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and
the Company is current in payment of the fees of the Depository Trust Company (or such other established clearing corporation) in connection
with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti&#45;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure;
10b-5</U>. The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and
schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, if any, at
the time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable
rules&nbsp;and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. The Preliminary Prospectus, Prospectus and the Prospectus Supplement, each as of its respective
date, comply in all material respects with the Securities Act and the Exchange Act and the applicable rules&nbsp;and regulations.
Each of the Preliminary Prospectus, Prospectus and the Prospectus Supplement, as amended or supplemented, did not and will not
contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading. The SEC Reports, when they were
filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable
rules&nbsp;and regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement of
a material fact or omitted to state a material fact necessary to make the statements therein (with respect to the SEC Reports
incorporated by reference in the Preliminary Prospectus, Prospectus or Prospectus Supplement), in light of the circumstances under
which they were made not misleading; and any further documents so filed and incorporated by reference in the Preliminary Prospectus,
Prospectus or Prospectus Supplement, when such documents are filed with the Commission, will conform in all material respects to the
requirements of the Exchange Act and the applicable rules&nbsp;and regulations, as applicable, and will not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the
circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any
facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the
information set forth therein is required to be filed with the Commission. There are no documents required to be filed with the
Commission in connection with the transaction contemplated hereby that (x)&nbsp;have not been filed as required pursuant to the
Securities Act or (y)&nbsp;will not be filed within the requisite time period. There are no contracts or other documents required to
be described in the Preliminary Prospectus, Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the
Registration Statement, which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause
this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval
provisions of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&#8217;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&#8217;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)&nbsp;the
current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within one year from the Closing Date. The SEC Reports sets forth as of the date hereof all outstanding secured and
unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company
nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required to be filed through the date hereof
(taking into account any valid extensions), (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are
material in amount, shown or determined to be due on such returns, reports and declarations and (iii)&nbsp;has set aside on its
books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. The provisions for
taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all
accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial
statements. The term &#8220;taxes&#8221; mean all federal, state, local, foreign, and other net income, gross income, gross
receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees,
assessments, or charges of a similar kind of nature, together with any interest and any penalties, additions to tax, or additional
amounts with respect thereto. The term &#8220;returns&#8221; means all returns, declarations, reports, statements, and other
documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA. The
Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply
in all material respects with the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
To the knowledge and belief of the Company, the Company Auditor (i)&nbsp;is an independent registered public accounting firm as required
by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements to be included in the Company&#8217;s
Annual Report for the fiscal year ending December&nbsp;31, 2022. The Company Auditor has not, during the periods covered by the financial
statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section&nbsp;10A(g)&nbsp;of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<U>FDA</U>&#8221;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<U>FDCA</U>&#8221;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<U>Pharmaceutical Product</U>&#8221;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules&nbsp;and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would
not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the
FDA or any other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of
advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold on any clinical
investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company or any of its Subsidiaries,
(v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&nbsp;otherwise
alleges any violation of any laws, rules&nbsp;or regulations by the Company or any of its Subsidiaries, and which, either individually
or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws, rules&nbsp;and regulations of the FDA.&nbsp; The Company has
not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i)&nbsp;in
accordance with the terms of the Company&#8217;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company&#8217;s stock option plan has been backdated. The Company has not knowingly granted, and there is
no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the
grant of stock options with, the release or other public announcement of material information regarding the Company or its
Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Representative&#8217;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &#8220;<U>BHCA</U>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<U>Federal
Reserve</U>&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &#8220;<U>Money Laundering Laws</U>&#8221;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&#8217;s knowledge, all information contained in the questionnaires completed by each of the Company&#8217;s
directors and officers immediately prior to the Offering and in the Lock-Up Agreement provided to the Underwriters is true and correct
in all material respects and the Company has not become aware of any information which would cause the information disclosed in such questionnaires
become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Affiliation</U>. To the Company&#8217;s knowledge, no officer, director or any beneficial owner of 5% or more of the Company&#8217;s unregistered
securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules&nbsp;and
regulations of FINRA) that is participating in the Offering. The Company will advise the Representative and EGS if it learns that any
officer, director or owner of 5% or more of the Company&#8217;s outstanding shares of Common Stock or Common Stock Equivalents is or becomes
an affiliate or associated person of a FINRA member firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&#8217;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative or EGS shall
be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
of Directors</U>. The Board of Directors is comprised of the persons set forth under the heading of the Prospectus captioned &#8220;Management.&#8221;
The qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley
Act of 2002 and the rules&nbsp;promulgated thereunder applicable to the Company and the rules&nbsp;of the Trading Market. At least one
member of the Board of Directors qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of
2002 and the rules&nbsp;promulgated thereunder and the rules&nbsp;of the Trading Market. In addition, at least a majority of the persons
serving on the Board of Directors qualify as &#8220;independent&#8221; as defined under the rules&nbsp;of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cybersecurity</U>.&nbsp;
(i)(x)&nbsp;There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<U>IT Systems
and Data</U>&#8221;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company
and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its Subsidiaries (i)&nbsp;are in compliance with all federal, state, local
and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<U>Hazardous Materials</U>&#8221;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<U>Environmental Laws</U>&#8221;);
(ii)&nbsp;have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses; and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in
each clause (i), (ii)&nbsp;and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
to Registration Statement</U>. The Company has delivered, or will as promptly as practicable deliver, or make available, to the Underwriters
complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part
thereof, and conformed copies of the Registration Statement (without exhibits), the Prospectus and the Prospectus Supplement, as amended
or supplemented, in such quantities and at such places as an Underwriter reasonably requests. Neither the Company nor any of its directors
and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material in connection with the
offering and sale of the Securities other than the Prospectus, the Prospectus Supplement, the Registration Statement, and copies of the
documents incorporated by reference therein. The Company shall not file any such amendment or supplement to which the Representative shall
reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Federal
Securities Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its best efforts to comply
with all requirements imposed upon it by the Securities Act and the rules&nbsp;and regulations thereunder and the Exchange Act and the
rules&nbsp;and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales of or dealings
in the Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating to the Securities
is required to be delivered under the Securities Act, any event shall have occurred as a result of which, in the opinion of counsel for
the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue statement of a material
fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply with the Securities Act,
the Company will notify the Underwriters promptly and prepare and file with the Commission, subject to Section&nbsp;4.1 hereof, an appropriate
amendment or supplement in accordance with Section&nbsp;10 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing
of Final Prospectus</U>. The Company will file the Prospectus (in form and substance satisfactory to the Representative) with the Commission
pursuant to the requirements of Rule&nbsp;424.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Registration</U>. For a period of three years from the Execution Date, the Company will use its best efforts to maintain the registration
of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock under the Exchange Act without the prior
written consent of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating to the Securities
that would constitute an issuer free writing prospectus, as defined in Rule&nbsp;433 of the rules&nbsp;and regulations under the Securities
Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative is herein
referred to as a <B>&#8220;</B><U>Permitted Free Writing Prospectus</U>.&#8221; The Company represents that it will treat each Permitted
Free Writing Prospectus as an &#8220;issuer free writing prospectus&#8221; as defined in rule&nbsp;and regulations under the Securities
Act, and has complied and will comply with the applicable requirements of Rule&nbsp;433 of the Securities Act, including timely Commission
filing where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to the Underwriters of Prospectuses</U>. The Company will deliver to the Underwriters, without charge, from time to time during the period
when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies of each Prospectus
as the Underwriters may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
and Events Requiring Notice to the Underwriters</U>. The Company will use its best efforts to cause the Registration Statement to remain
effective with a current prospectus until the later of nine (9)&nbsp;months from the Execution Date and the date on which the Warrants
are no longer outstanding, and will notify the Underwriters and holders of the Warrants immediately and confirm the notice in writing:
(i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of the issuance by the Commission of
any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&nbsp;of the issuance by any state securities
commission of any proceedings for the suspension of the qualification of the Securities for offering or sale in any jurisdiction or of
the initiation, or the threatening, of any proceeding for that purpose; (iv)&nbsp;of the mailing and delivery to the Commission for filing
of any amendment or supplement to the Registration Statement or Prospectus, provided that the filing of an amendment or supplement to
the Registration Statement on the SEC&#8217;s EDGAR system shall be deemed to be such notification; (v)&nbsp;of the receipt of any comments
or request for any additional information from the Commission; and (vi)&nbsp;of the happening of any event during the period described
in this Section&nbsp;4.4 that, in the judgment of the Company, causes the Registration Statement or the Prospectus, as the case may be,
to include an untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter
a stop order or suspend such qualification at any time, the Company will make every reasonable effort to obtain promptly the lifting of
such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Review
of Financial Statements</U>. For a period of five (5)&nbsp;years from the Execution Date, the Company, at its expense, shall cause its
regularly engaged independent registered public accountants to review (but not audit) the Company&#8217;s financial statements for each
of the first three fiscal quarters prior to the announcement of quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses
of the Offering</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and each Option Closing Date, if any,
to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (a)&nbsp;all filing fees and communication expenses relating to the registration of the Securities to be
sold in the Offering (including the Option Securities) with the Commission; (b)&nbsp;all FINRA Public Offering Filing System fees associated
with the review of the Offering by FINRA; (c)&nbsp;all fees and expenses relating to the listing of such Closing Shares, Option Shares
and Underlying Shares on the Trading Market and such other stock exchanges as the Company and the Representative together determine; (d)&nbsp;all
fees, expenses and disbursements relating to the registration or qualification of such Securities under the &#8220;blue sky&#8221; securities
laws of such states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation, all
filing and registration fees, and the fees and expenses of Blue Sky counsel); (e)&nbsp;the costs of all mailing and printing of the underwriting
documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers&#8217; Agreement, Underwriters&#8217; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem
necessary; (f)&nbsp;the costs and expenses of the Company&#8217;s public relations firm; (g)&nbsp;the costs of preparing, printing and
delivering the Securities; (h)&nbsp;fees and expenses of the Transfer Agent for the Securities (including, without limitation, any fees
required for same-day processing of any instruction letter delivered by the Company and fees and expenses pursuant to the Warrant Agency
Agreement and the Preferred Stock Agency Agreement); (i)&nbsp;stock transfer and/or stamp taxes, if any, payable upon the transfer of
securities from the Company to the Underwriters; (j)&nbsp;the fees and expenses of the Company&#8217;s accountants; (k)&nbsp;the fees
and expenses of the Company&#8217;s legal counsel and other agents and representatives; (l)&nbsp;the Underwriters&#8217; costs of mailing
prospectuses to prospective investors; and (m)&nbsp;the costs associated with advertising the Offering in the national editions of the
Wall Street Journal and New York Times after the Closing Date. The Underwriters may also deduct from the net proceeds of the Offering
payable to the Company on the Closing Date, or each Option Closing Date, if any, the expenses set forth herein to be paid by the Company
to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses
of the Representative</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section&nbsp;4.6(a), on the
Closing Date it will reimburse the Representative for its reasonable, out-of-pocket expenses incurred, including travel, databases, fees
and disbursements of legal counsel, and of other consultants and advisors not to exceed $105,000 without the Company&#8217;s prior consent
by deduction from the proceeds of the Offering contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application
described under the caption &#8220;Use of Proceeds&#8221; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Earnings Statements to Security Holders</U>. The Company will make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement (which need
not be certified by independent public or independent certified public accountants unless required by the Securities Act or the Rules&nbsp;and
Regulations under the Securities Act, but which shall satisfy the provisions of Rule&nbsp;158(a)&nbsp;under Section&nbsp;11(a)&nbsp;of
the Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stabilization</U>.
Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal
Controls</U>. The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i)&nbsp;transactions
are executed in accordance with management&#8217;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary
in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii)&nbsp;access
to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv)&nbsp;the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period of at least three
years after the Execution Date. The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA</U>.
The Company shall advise the Underwriters (who shall make an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder
of the Company becomes an affiliate or associated person of an Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&#8217; responsibility to the Company is solely
contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates or
any selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any
of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding
anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the
success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the
Company by the Underwriters for the shares and the Underwriters have no obligation to disclose, or account to the Company for, any
of such additional financial interests. The Company hereby waives and releases, to the fullest extent permitted by law, any claims
that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underlying
Shares</U>. The shares of Common Stock underlying the Preferred Stock shall be issued free of legends. If all or any portion of a Warrant
is exercised at a time when there is an effective registration statement to cover the issuance of the Warrant Shares or if the Warrant
is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all restrictive legends.
If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or
resale of the Warrant Shares) is not effective or is not otherwise available for the sale of the Warrant Shares, the Company shall immediately
notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify
such holders when the registration statement is effective again and available for the sale of the Warrant Shares (it being understood
and agreed that the foregoing shall not limit the ability of the Company to issue, or any holder thereof to sell, any of the Warrant Shares
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as board members
and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated thereunder
and with the listing requirements of the Trading Market and (ii)&nbsp;if applicable, at least one member of the Board of Directors qualifies
as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. At the request of the Representative, by 9:00 a.m.&nbsp;(New York City time) on the date hereof, the Company
shall issue a press release disclosing the material terms of the Offering. The Company and the Representative shall consult with each
other in issuing any other press releases with respect to the Offering, and neither the Company nor any Underwriter shall issue any such
press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release
of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of the Company, which consent
shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. The Company will not issue press releases
or engage in any other publicity, without the Representative&#8217;s prior written consent, for a period ending at 5:00 p.m.&nbsp;(New
York City time) on the first business day following the 45th day following the Closing Date, other than normal and customary releases
issued in the ordinary course of the Company&#8217;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Underwriter
of the Securities is an &#8220;Acquiring Person&#8221; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares
and Conversion Shares pursuant to this Agreement and, at or prior to the Authorized Share Increase Date, shall reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Closing
Shares, Option Shares and Underlying Shares on such Trading Market and promptly secure the listing of all of the Closing Shares, Option
Shares and Underlying Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded
on any other Trading Market, it will then include in such application all of the Closing Shares, Option Shares and Underlying Shares,
and will take such other action as is necessary to cause all of the Closing Shares, Option Shares and Underlying Shares to be listed or
quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the
listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing
and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility of the Common
Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer. In addition, the Company shall hold an annual or special meeting of stockholders on or prior to September&nbsp;23, 2022 for
the purpose of obtaining Authorized Share Approval and Shareholder Approval, with the recommendation of the Company&#8217;s Board of Directors
that such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner
as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor
of such proposals. If the Company does not obtain Authorized Share Approval and Shareholder Approval at the first meeting, the Company
shall call a meeting every thirty (30) days thereafter to seek Authorized Share Approval and Shareholder Approval until the earlier of
the date on which Authorized Share Approval and Shareholder Approval are obtained or the Warrants are no longer outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the later of (i)&nbsp;ninety (90) days following the Closing Date and (ii)&nbsp;thirty (30) days following the later
of (x)&nbsp;the Authorized Share Increase Date and (y)&nbsp;the date Shareholder Approval is received and effective, neither the Company
nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common
Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until one hundred eighty (180) following the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &#8220;<U>Variable Rate Transaction</U>&#8221; means a transaction in which the
Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other
price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or effects
a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities
at a future determined price; provided however, that after ninety (90) days following the Closing Date, the Company&#8217;s issuance of
shares of Common Stock pursuant to an at-the-market offering facility with the Representative shall not be deemed a Variable Rate Transaction
hereunder. Any Underwriter shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy
shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section&nbsp;4.20 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Research
Independence</U>. The Company acknowledges that each Underwriter&#8217;s research analysts and research departments, if any, are required
to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and
that such Underwriter&#8217;s research analysts may hold and make statements or investment recommendations and/or publish research reports
with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases,
to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of
interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be
different from or inconsistent with the views or advice communicated to the Company by such Underwriter&#8217;s investment banking divisions.
The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable
securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or
equity securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFAULT BY UNDERWRITERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If on the Closing Date or
any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the Closing Securities or Option Securities,
as the case may be, which such Underwriter has agreed to purchase and pay for on such date (otherwise than by reason of any default on
the part of the Company), the Representative, or if the Representative is the defaulting Underwriter, the non-defaulting Underwriters,
shall use their reasonable efforts to procure within 36 hours thereafter one or more of the other Underwriters, or any others, to purchase
from the Company such amounts as may be agreed upon and upon the terms set forth herein, the Closing Securities or Option Securities,
as the case may be, which the defaulting Underwriter or Underwriters failed to purchase. If during such 36 hours the Representative shall
not have procured such other Underwriters, or any others, to purchase the Closing Securities or Option Securities, as the case may be,
agreed to be purchased by the defaulting Underwriter or Underwriters, then (a)&nbsp;if the aggregate number of Closing Securities or Option
Securities, as the case may be, with respect to which such default shall occur does not exceed 10% of the Closing Securities or Option
Securities, as the case may be, covered hereby, the other Underwriters shall be obligated, severally, in proportion to the respective
numbers of Closing Securities or Option Securities, as the case may be, which they are obligated to purchase hereunder, to purchase the
Closing Securities or Option Securities, as the case may be, which such defaulting Underwriter or Underwriters failed to purchase, or
(b)&nbsp;if the aggregate number of Closing Securities or Option Securities, as the case may be, with respect to which such default shall
occur exceeds 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the Company or the Representative
will have the right to terminate this Agreement without liability on the part of the non-defaulting Underwriters or of the Company except
to the extent provided in Article&nbsp;VI hereof. In the event of a default by any Underwriter or Underwriters, as set forth in this Article&nbsp;V,
the applicable Closing Date may be postponed for such period, not exceeding seven days, as the Representative, or if the Representative
is the defaulting Underwriter, the non-defaulting Underwriters, may determine in order that the required changes in the Prospectus or
in any other documents or arrangements may be effected. The term &#8220;Underwriter&#8221; includes any Person substituted for a defaulting
Underwriter. Any action taken under this Section&nbsp;shall not relieve any defaulting Underwriter from liability in respect of any default
of such Underwriter under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VI.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of the Underwriters</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Underwriters,
and each dealer selected by each Underwriter that participates in the offer and sale of the Securities (each a &#8220;<U>Selected Dealer</U>&#8221;)
and each of their respective directors, officers and employees and each Person, if any, who controls such Underwriter or any Selected
Dealer (&#8220;<U>Controlling Person</U>&#8221;) within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal
or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any
claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such Underwriter and any third
party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or
at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue
statement of a material fact contained in (i)&nbsp;any Preliminary Prospectus, if any, the Registration Statement or the Prospectus (as
from time to time each may be amended and supplemented); (ii)&nbsp;any materials or information provided to investors by, or with the
approval of, the Company in connection with the marketing of the offering of the Securities, including any &#8220;road show&#8221; or
investor presentations made to investors by the Company (whether in person or electronically); or (iii)&nbsp;any application or other
document or written communication (in this Article&nbsp;VI, collectively called &#8220;<U>application</U>&#8221;) executed by the Company
or based upon written information furnished by the Company in any jurisdiction in order to qualify the Securities under the securities
laws thereof or filed with the Commission, any state securities commission or agency, Trading Market or any securities exchange; or the
omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon and
in conformity with written information furnished to the Company with respect to the applicable Underwriter by or on behalf of such Underwriter
expressly for use in any Preliminary Prospectus, if any, the Registration Statement or Prospectus, or any amendment or supplement thereto,
or in any application, as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made
in the Preliminary Prospectus, if any, the indemnity agreement contained in this Section&nbsp;6.1 shall not inure to the benefit of an
Underwriter to the extent that any loss, liability, claim, damage or expense of such Underwriter results from the fact that a copy of
the Prospectus was not given or sent to the Person asserting any such loss, liability, claim or damage at or prior to the written confirmation
of sale of the Securities to such Person as required by the Securities Act and the rules&nbsp;and regulations thereunder, and if the untrue
statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance
by the Company with its obligations under this Agreement. The Company agrees promptly to notify each Underwriter of the commencement of
any litigation or proceedings against the Company or any of its officers, directors or Controlling Persons in connection with the issue
and sale of the Public Securities or in connection with the Registration Statement or Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.
If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity may be sought
against the Company pursuant to Section&nbsp;6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case may be, shall
promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including
the employment and fees of counsel (subject to the reasonable approval of such Underwriter or such Selected Dealer, as the case may be)
and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall have the right to employ its or their
own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter, such Selected Dealer
or Controlling Person unless (i)&nbsp;the employment of such counsel at the expense of the Company shall have been authorized in writing
by the Company in connection with the defense of such action, or (ii)&nbsp;the Company shall not have employed counsel to have charge
of the defense of such action, or (iii)&nbsp;such indemnified party or parties shall have reasonably concluded that there may be defenses
available to it or them which are different from or additional to those available to the Company (in which case the Company shall not
have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable
fees and expenses of not more than one additional firm of attorneys selected by such Underwriter (in addition to local counsel), Selected
Dealer and/or Controlling Person shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter,
Selected Dealer or Controlling Person shall assume the defense of such action as provided above, the Company shall have the right to approve
the terms of any settlement of such action which approval shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of the Company</U>. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors,
officers and employees and agents who control the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company
to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made
in any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or in any application,
in reliance upon, and in strict conformity with, written information furnished to the Company with respect to such Underwriter by or on
behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment
or supplement thereto or in any such application. In case any action shall be brought against the Company or any other Person so indemnified
based on any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or any application,
and in respect of which indemnity may be sought against such Underwriter, such Underwriter shall have the rights and duties given to the
Company, and the Company and each other Person so indemnified shall have the rights and duties given to such Underwriter by the provisions
of this Article&nbsp;VI. Notwithstanding the provisions of this Section&nbsp;6.3, no Underwriter shall be required to indemnify the Company
for any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter. The
Underwriters' obligations in this Section&nbsp;6.3 to indemnify the Company are several in proportion to their respective underwriting
obligations and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Rights</U>. In order to provide for just and equitable contribution under the Securities Act in any case in which (i)&nbsp;any Person
entitled to indemnification under this Article&nbsp;VI makes a claim for indemnification pursuant hereto but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article&nbsp;VI
provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act, the Exchange Act or otherwise may be required
on the part of any such Person in circumstances for which indemnification is provided under this Article&nbsp;VI, then, and in each such
case, the Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities, claims, damages
and expenses of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such
proportions that such Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing
on the cover page&nbsp;of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the
balance; provided, that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section,
each director, officer and employee of such Underwriter or the Company, as applicable, and each Person, if any, who controls such Underwriter
or the Company, as applicable, within the meaning of Section&nbsp;15 of the Securities Act shall have the same rights to contribution
as such Underwriter or the Company, as applicable. Notwithstanding the provisions of this Section&nbsp;6.4, no Underwriter shall be required
to contribute any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter.
The Underwriters' obligations in this Section&nbsp;6.4 to contribute are several in proportion to their respective underwriting obligations
and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Procedure</U>. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the
commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made
against another party (&#8220;<U>contributing party</U>&#8221;), notify the contributing party of the commencement thereof, but the
failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than
for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a
contributing party or its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will
be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such
contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or
proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution
provisions contained in this Section&nbsp;6.4 are intended to supersede, to the extent permitted by law, any right to contribution
under the Securities Act, the Exchange Act or otherwise available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VII.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Right</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, by notice to the
Company: (i)&nbsp;if any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the
immediate future materially disrupt, general securities markets in the United States; or (ii)&nbsp;if trading on any Trading Market shall
have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices
for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction,
or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities, or (iv)&nbsp;if a banking
moratorium has been declared by a New York State or federal authority, or (v)&nbsp;if a moratorium on foreign exchange trading has been
declared which materially adversely impacts the United States securities markets, or (vi)&nbsp;if the Company shall have sustained a material
loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss
shall have been insured, will, in the Representative&#8217;s reasonable opinion, make it inadvisable to proceed with the delivery of the
Securities, or (vii)&nbsp;if the Company is in material breach of any of its representations, warranties or covenants hereunder, or (viii)&nbsp;if
the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the
Company, or such adverse material change in general market conditions as in the Representative&#8217;s judgment would make it impracticable
to proceed with the offering, sale and/or delivery of the Securities or to enforce contracts made by the Underwriters for the sale of
the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
In the event this Agreement shall be terminated pursuant to Section&nbsp;7.1(a), within the time specified herein or any extensions thereof
pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable out of pocket expenses
related to the transactions contemplated herein then due and payable, including the fees and disbursements of EGS up to $50,000 (<U>provided</U>,
<U>however</U>, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether
or not this Agreement is otherwise carried out, the provisions of Article&nbsp;VI shall not be in any way effected by such election or
termination or failure to carry out the terms of this Agreement or any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules. Notwithstanding anything herein to the contrary, the Investment Banking Agreement, dated February&nbsp;28, 2022,
as amended on July&nbsp;12, 2022 and July&nbsp;20, 2022 (&#8220;<U>Engagement Agreement</U>&#8221;), by and between the Company and the
Representative, shall continue to be effective and the terms therein, including, without limitation, Section&nbsp;4(b)&nbsp;and Section&nbsp;5
with respect to any future offerings, shall continue to survive and be enforceable by the Representative in accordance with its terms,
provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement
shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
e-mail attachment at the email address set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York City
time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via
e-mail attachment at the e-mail address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or
later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the date
of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and the Representative. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or
Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is
improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an
Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company
under Article&nbsp;VI, the prevailing party in such Action or Proceeding shall be reimbursed by the other party for its reasonable
attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or
Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the Option Closing, if any, and the delivery of the
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page&nbsp;were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Underwriters
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.12&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the
next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY RIGHT TO TRIAL
BY JURY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement among the Company and the several Underwriters in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">KIORA PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Brian M. Strem, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Name: Brian M. Strem, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 204pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1371 East 2100 South, Suite&nbsp;200&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Salt Lake City, UT 84105&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Copy to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Burns&nbsp;&amp; Levinson LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">125 High Street&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, MA 02110&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Robert Petitt,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted on the date first above written.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LADENBURG THALMANN&nbsp;&amp; CO. INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As the Representative of the several&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriters listed on Schedule I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Nicholas Stergis&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Nicholas Stergis&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">640 Fifth Avenue, 4<SUP>th</SUP> Floor&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10019&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copy to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ellenoff Grossman&nbsp;&amp; Schole LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1345 Avenue of the Americas&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Michael Nertney,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Schedule
of Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Underwriters</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Closing <BR>
Shares</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Closing<BR>
 Preferred<BR>
 Shares</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Closing Class&nbsp;A<BR>
 Warrants</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Closing Class&nbsp;B<BR>
 Warrants</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Closing Purchase<BR>
 Price</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left; padding-bottom: 1pt">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">19,770,172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,280</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">26,170,172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">26,170,172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">4,815,311.65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">19,770,172</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,280</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">26,170,172</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">26,170,172</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,815,311.65</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>tm2221834d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>KIORA
PHARMACEUTICALS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RIGHTS AND LIMITATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES <FONT STYLE="text-transform: uppercase">E
</FONT>CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">PURSUANT
TO SECTION&nbsp;151 OF THE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Delaware
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned, Brian M.
Strem, Ph.D., does hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">1. He is the President, Chief
Executive Officer and Secretary of Kiora Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &#8220;<U>Corporation</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">2. The Corporation is authorized
to issue 10,000,000 shares of preferred stock, 15,445.9 of which have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">3. The following resolutions
were duly adopted by the board of directors of the Corporation (the &#8220;<U>Board of Directors</U>&#8221;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the certificate
of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares,
$0.01 par value per share, issuable from time to time in one or more series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the Board of Directors
is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation
preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof,
of any of them; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, it is the desire
of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating
to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Underwriting Agreement, up to 1,280 shares
of the preferred stock which the Corporation has the authority to issue, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NOW, THEREFORE, BE IT RESOLVED,
that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities,
rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of
preferred stock as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS OF PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;1</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Affiliate</U>&#8221;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Alternate
Consideration</U>&#8221; shall have the meaning set forth in Section&nbsp;7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Beneficial
Ownership Limitation</U>&#8221; shall have the meaning set forth in Section&nbsp;6(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Business
Day</U>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Buy-In</U>&#8221;
shall have the meaning set forth in Section&nbsp;6(c)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Commission</U>&#8221;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Common
Stock</U>&#8221; means the Corporation&#8217;s common stock, par value $0.01 per share, and stock of any other class of securities into
which such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Common
Stock Equivalents</U>&#8221; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Amount</U>&#8221; means the sum of the Stated Value at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Date</U>&#8221; shall have the meaning set forth in Section&nbsp;6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Price</U>&#8221; shall have the meaning set forth in Section&nbsp;6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Conversion
Shares</U>&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance
with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Exchange
Act</U>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Fundamental
Transaction</U>&#8221; shall have the meaning set forth in Section&nbsp;7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>GAAP</U>&#8221;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Holder</U>&#8221;
shall have the meaning given such term in Section&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Liquidation</U>&#8221;
shall have the meaning set forth in Section&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>New York
Courts</U>&#8221; shall have the meaning set forth in Section&nbsp;8(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Notice
of Conversion</U>&#8221; shall have the meaning set forth in Section&nbsp;6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Original
Issue Date</U>&#8221; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers
of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Person</U>&#8221;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Preferred
Stock</U>&#8221; shall have the meaning set forth in Section&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Representative</U>&#8221;
means Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Securities
Act</U>&#8221; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Share
Delivery Date</U>&#8221; shall have the meaning set forth in Section&nbsp;6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Stated
Value</U>&#8221; shall have the meaning set forth in Section&nbsp;2, as the same may be increased pursuant to Section&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Successor
Entity</U>&#8221; shall have the meaning set forth in Section&nbsp;7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Day</U>&#8221; means a day on which the principal Trading Market is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Market</U>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Transfer
Agent</U>&#8221; means VStock Transfer, LLC, the current transfer agent of the Corporation with a mailing address of 18 Lafayette Place,
Woodmere, New York 11598 and an email address of 0-k@vstocktransfer.com, and any successor transfer agent of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Underwriting
Agreement</U>&#8221; means the underwriting agreement, dated as of July&nbsp;22, 2022, among the Corporation and the Representative, as
representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;2</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Designation,
Amount and Par Value</U>. The series of preferred stock shall be designated as its Series&nbsp;E Convertible Preferred Stock (the &#8220;<U>Preferred
Stock</U>&#8221;) and the number of shares so designated shall be up to 1,280 (which shall not be subject to increase without the written
consent of the holders of a majority of the then outstanding shares of the Preferred Stock (each, a &#8220;<U>Holder</U>&#8221; and collectively,
the &#8220;<U>Holders</U>&#8221;)). Each share of Preferred Stock shall have a par value of $0.01 per share and a stated value equal to
$1,000, subject to increase set forth in Section&nbsp;3 below (the &#8220;<U>Stated Value</U>&#8221;). The Preferred Stock will initially
be issued in book-entry form and shall initially be represented only by one or more global certificates deposited with the Depository
Trust Company (&#8220;<U>DTC</U>&#8221;) and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC, or as otherwise directed
by DTC. As between the Corporation and a beneficial owner of Preferred Stock shall have all of the rights and remedies of a Holder hereunder.
In addition, a beneficial owner of Preferred Stock has the right, upon written notice by such beneficial owner to the Corporation, to
request the exchange of some or all of such beneficial owner&#8217;s interest in Preferred Stock represented by one or more global Preferred
Stock certificates deposited with Cede&nbsp;&amp; Co. (or its successor) for a physical Preferred Stock certificate (a &#8220;<U>Preferred
Stock Certificate Request Notice</U>&#8221; and the date of delivery of such Preferred Stock Certificate Request Notice by a beneficial
owner, the &#8220;<U>Preferred Stock Certificate Request Notice Date</U>&#8221; and the deemed surrender upon delivery by the beneficial
owner of a number of global shares of Preferred Stock for the same number of shares of Preferred Stock represented by a physical stock
certificate, a &#8220;<U>Preferred Stock Exchange</U>&#8221;, and such physical certificate(s), a &#8220;<U>Preferred Stock Certificate</U>&#8221;).
Upon delivery of a Preferred Stock Certificate Request Notice, the Corporation shall promptly effect the Preferred Stock Exchange and
shall promptly issue and deliver to the beneficial owner a physical Preferred Stock Certificate for such number of shares of Preferred
Stock represented by its interest in such global certificates in the name of the beneficial owner. Such Preferred Stock Certificate shall
be dated the original issue date and shall be executed by an authorized signatory of the Corporation. In connection with a Preferred Stock
Exchange, the Corporation agrees to deliver the Preferred Stock Certificate to the Holder within two (2)&nbsp;Business Days of the delivery
of a properly completed and executed Preferred Stock Certificate Request Notice pursuant to the delivery instructions in the Preferred
Stock Certificate Request Notice. The Corporation covenants and agrees that, upon the date of delivery of the properly completed and executed
Preferred Stock Certificate Request Notice, the Holder shall be deemed to be the holder of the Preferred Stock Certificate and further,
for purposes of Regulation SHO, a Holder whose interest in this Preferred Stock is a beneficial interest in certificate(s)&nbsp;representing
this Preferred Stock held in book-entry form through DTC shall be deemed to have converted its interest in this Preferred Stock upon instructing
its broker that is a DTC participant to convert its interest in this Preferred Stock, and, notwithstanding anything to the contrary set
forth herein, the Preferred Stock Certificate shall be deemed for all purposes to represent all of the terms and conditions of the Preferred
Stock evidenced by such global Preferred Stock certificates and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;3</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>.
Except for stock dividends or distributions for which adjustments are to be made pursuant to Section&nbsp;7, Holders shall be entitled
to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis,
disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the
Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares of Preferred
Stock. The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously complies with this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;4</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting
Rights</U>. Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights. However,
as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a
majority of the then outstanding shares of the Preferred Stock, (a)&nbsp;alter or change adversely the powers, preferences or rights given
to the Preferred Stock or alter or amend this Certificate of Designation, (b)&nbsp;amend its certificate of incorporation or other charter
documents in any manner that adversely affects any rights of the Holders, (c)&nbsp;increase the number of authorized shares of Preferred
Stock, or (d)&nbsp;enter into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;5</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation</U>.
Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &#8220;<U>Liquidation</U>&#8221;),
the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder
of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder)
to Common Stock which amounts shall be paid pari passu with all holders of Common Stock. The Corporation shall mail written notice of
any such Liquidation, not less than forty-five (45) days prior to the payment date stated therein, to each Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;6</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversions
at Option of Holder</U>. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original
Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section&nbsp;6(d))
determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by
providing the Corporation with the form of conversion notice attached hereto as <U>Annex A</U> (a &#8220;<U>Notice of Conversion</U>&#8221;).
Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock
owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date
on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by e-mail such Notice
of Conversion to the Corporation (such date, the &#8220;<U>Conversion Date</U>&#8221;). If no Conversion Date is specified in a Notice
of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder.
No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Conversion form be required. The calculations and entries set forth in the Notice of Conversion shall control in the
absence of manifest or mathematical error. To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender
the certificate(s)&nbsp;representing the shares of Preferred Stock to the Corporation unless all of the shares of Preferred Stock represented
thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Preferred Stock promptly
following the Conversion Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed in accordance with the terms
hereof shall be canceled and shall not be reissued. Notwithstanding the foregoing in this Section&nbsp;6(a), a holder whose interest in
the Preferred Stock is a beneficial interest in certificate(s)&nbsp;representing the Preferred Stock held in book-entry form through DTC
(or another established clearing corporation performing similar functions), shall effect conversions made pursuant to this Section&nbsp;6(a)&nbsp;by
delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for conversion, complying with
the procedures to effect conversions that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder&#8217;s
right to elect to receive Preferred Stock in certificated form pursuant to Section&nbsp;2, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
Price</U>. The conversion price for the Preferred Stock shall equal <B>$0.20</B>, subject to adjustment herein (the &#8220;<U>Conversion
Price</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Conversion</U></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of
Trading Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &#8220;<U>Share Delivery Date</U>&#8221;),
the Corporation shall deliver, or cause to be delivered, to the converting Holder (A)&nbsp;the number of Conversion Shares being acquired
upon the conversion of the Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions, and
(B)&nbsp;a bank check in the amount of accrued and unpaid dividends, if any. The Corporation shall use its best efforts to deliver the
Conversion Shares required to be delivered by the Corporation under this Section&nbsp;6 electronically through the Depository Trust Company
or another established clearing corporation performing similar functions. As used herein, &#8220;<U>Standard Settlement Period</U>&#8221;
means the standard settlement period, expressed in a number of Trading Days, on the Corporation&#8217;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Conversion. Notwithstanding the foregoing, with respect to any
Notice(s)&nbsp;of Conversion delivered by 12:00 p.m.&nbsp;(New York City time) on the Original Issue Date, the Corporation agrees to deliver
the Conversion Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Original Issue Date, and the Original
Issue Date being deemed the &#8220;Share Delivery Date&#8221; with respect to any Notice(s)&nbsp;of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed
by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any
time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall promptly return
to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation
the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligation
Absolute; Partial Liquidated Damages</U>. The Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon
conversion of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or
inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment
against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any
breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged
violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such
obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>,
that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such
Holder. In the event a Holder shall elect to convert any or all of the Stated Value of its Preferred Stock, the Corporation may not
refuse conversion based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any
violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or
enjoining conversion of all or part of the Preferred Stock of such Holder shall have been sought and obtained, and the Corporation
posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated Value of Preferred Stock which is subject to
the injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the
proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the
Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed conversion. If the Corporation fails to
deliver to a Holder such Conversion Shares pursuant to Section&nbsp;6(c)(i)&nbsp;by the Share Delivery Date applicable to such
conversion, the Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated
Value of Preferred Stock being converted, $50 per Business Day (increasing to $100 per Business Day on the third Business Day and
increasing to $200 per Business Day on the tenth Business Day after such Share Delivery Date) for each Business Day after the Share
Delivery Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a
Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period
specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not
prohibit a Holder from seeking to enforce damages pursuant to any other Section&nbsp;hereof or under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant to
Section&nbsp;6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market
transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share
Delivery Date (a &#8220;<U>Buy-In</U>&#8221;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other
remedies available to or elected by such Holder) the amount, if any, by which (x)&nbsp;such Holder&#8217;s total purchase price (including
any brokerage commissions) for the Common Stock so purchased exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of
Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which
the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of
such Holder, either reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred Stock submitted
for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of Common Stock
that would have been issued if the Corporation had timely complied with its delivery requirements under Section&nbsp;6(c)(i). For example,
if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion
of shares of Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions)
giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the immediately preceding sentence, the Corporation
shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice indicating the amounts payable to
such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of such loss. Nothing herein shall limit
a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver the Conversion Shares
upon conversion of the shares of Preferred Stock as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available out of its authorized
and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock as herein provided, free from
preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred
Stock), not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments and
restrictions of Section&nbsp;7) upon the conversion of the then outstanding shares of Preferred Stock. The Corporation covenants that
all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent
with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from
converting fractional shares of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge to any Holder
for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided
that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and
delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares of Preferred Stock and
the Corporation shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the
issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation
that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion
and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Conversion Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Beneficial
Ownership Limitation</U>. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right
to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable
Notice of Conversion, such Holder (together with such Holder&#8217;s Affiliates, and any Persons acting as a group together with such
Holder or any of such Holder&#8217;s Affiliates (such Persons, &#8220;<U>Attribution Parties</U>&#8221;)) would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock
issuable upon conversion of the Preferred Stock with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which are issuable upon (i)&nbsp;conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially
owned by such Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted
portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained
herein (including, without limitation, the Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution
Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;6(d), beneficial ownership shall be calculated
in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. To the extent
that the limitation contained in this Section&nbsp;6(d)&nbsp;applies, the determination of whether the Preferred Stock is convertible
(in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and of how many shares of
Preferred Stock are convertible shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be
deemed to be such Holder&#8217;s determination of whether the shares of Preferred Stock may be converted (in relation to other securities
owned by such Holder together with any Affiliates and Attribution Parties) and how many shares of the Preferred Stock are convertible,
in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to
represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions
set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination. In
addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;6(d), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the
most recent of the following: (i)&nbsp;the Corporation&#8217;s most recent periodic or annual report filed with the Commission, as the
case may be, (ii)&nbsp;a more recent public announcement by the Corporation or (iii)&nbsp;a more recent written notice by the Corporation
or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request (which may
be via email) of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number of shares
of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<U>Beneficial
Ownership Limitation</U>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any shares of Preferred Stock,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon conversion of Preferred Stock held by the applicable Holder. A Holder, upon notice to the Corporation, may increase or
decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;6(d)&nbsp;applicable to its Preferred Stock provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon conversion of this Preferred Stock held by the Holder and the provisions
of this Section&nbsp;6(d)&nbsp;shall continue to apply. Any such increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Corporation and shall only apply to such Holder and no other Holder.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section&nbsp;6(d)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;7</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Stock Splits</U>. If the Corporation, at any time while this Preferred Stock is outstanding: (i)&nbsp;pays a stock dividend
or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock
Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of,
or payment of a dividend on, this Preferred Stock), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares,
(iii)&nbsp;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or
(iv)&nbsp;issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then
the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding
any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section&nbsp;7(a)&nbsp;shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
shall become effective immediately after the effective date in the case of a subdivision, combination or re&#45;classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;7(a)&nbsp;above, if at any time the Corporation grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &#8220;<U>Purchase Rights</U>&#8221;), then the Holder of will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete conversion of such Holder&#8217;s Preferred Stock (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<U>Distribution</U>&#8221;),
at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, to the extent that the Holder's right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Preferred Stock is outstanding, (i)&nbsp;the Corporation, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii)&nbsp;the
Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv)&nbsp;the Corporation, directly or indirectly, in one or more related
transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v)&nbsp;the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of
arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not
including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with
the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
 &#8220;<U>Fundamental Transaction</U>&#8221;), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have
the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the
occurrence of such Fundamental Transaction (without regard to any limitation in Section&nbsp;6(d)&nbsp;on the conversion of this
Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the
surviving corporation, and any additional consideration (the &#8220;<U>Alternate Consideration</U>&#8221;) receivable as a result of
such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible
immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;6(d)&nbsp;on the conversion of
this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred
Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the
Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and
conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217;
right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a
Fundamental Transaction in which the Corporation is not the survivor (the &#8220;<U>Successor Entity</U>&#8221;) to assume in
writing all of the obligations of the Corporation under this Certificate of Designation in accordance with the provisions of this
Section&nbsp;7(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of
such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of
this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental
Transaction, and with a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking
into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares
of capital stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic
value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Certificate of Designation referring to the &#8220;Corporation&#8221; shall refer instead to the Successor Entity), and may exercise
every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of
Designation with the same effect as if such Successor Entity had been named as the Corporation herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section&nbsp;7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to the Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section&nbsp;7, the Corporation shall
promptly deliver to each Holder by email a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Conversion by Holder</U>. If (A)&nbsp;the Corporation shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B)&nbsp;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C)&nbsp;the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the
Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the
Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property or (E)&nbsp;the Corporation shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the
Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Preferred Stock, and
shall cause to be delivered by email to each Holder at its last email address as it shall appear upon the stock books of the
Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to convert the
Conversion Amount of this Preferred Stock (or any part hereof) during the 20-day period commencing on the date of such notice
through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section&nbsp;8</U>.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Conversion, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Corporation, at the address set forth above, Attention: Chief Executive Officer, e-mail address bstrem@kiorapharma.com,
or such other e-mail address or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance
with this Section&nbsp;8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall
be in writing and delivered personally, e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder
at the e-mail address or address of such Holder appearing on the books of the Corporation. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is
delivered via e-mail at the e-mail address set forth in this Section&nbsp;8 prior to 5:30 p.m.&nbsp;(New York City time) on any date,
(ii)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section&nbsp;on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day,
(iii)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon
actual receipt by the party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Absolute
Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the obligation
of the Corporation, which is absolute and unconditional, to pay liquidated damages, and accrued dividends, as applicable, on the shares
of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost
or Mutilated Preferred Stock Certificate</U>. If a Holder&#8217;s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed,
the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu
of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost,
stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof
reasonably satisfactory to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall
be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles
of conflict of laws thereof. All legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated
by this Certificate of Designation (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders,
employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &#8220;<U>New
York Courts</U>&#8221;). The Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction of the New York Courts
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding. The Corporation
and each Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party
at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by applicable law. The Corporation and each Holder hereto hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate
of Designation or the transactions contemplated hereby. If the Corporation or any Holder shall commence an action or proceeding to enforce
any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other
party for its attorneys&#8217; fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action
or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver
by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation
on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist
upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation
or a Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to
all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the
applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate
of interest permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Next
Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Status
of Converted or Redeemed Preferred Stock</U>. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be
designated as Series&nbsp;E Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RESOLVED, FURTHER, that the Chairman, the president
or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed
to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution
and the provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the undersigned
has executed this Certificate this 22nd day of July, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Brian M. Strem, Ph.D.</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Brian M. Strem, Ph.D. &nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President, Chief Executive
    Officer and Secretary &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">(To be
Executed by the Registered Holder in order to Convert Shares of Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby elects to convert the number
of shares of Series&nbsp;E Convertible Preferred Stock indicated below into shares of common stock, par value $0.01 per share (the &#8220;<U>Common
Stock</U>&#8221;), of Kiora Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &#8220;<U>Corporation</U>&#8221;), according to the
conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned,
the undersigned will pay all transfer taxes payable with respect thereto. No fee will be charged to the Holders for any conversion, except
for any such transfer taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 18%">Date to Effect Conversion:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 62%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 42%">Number of shares of Preferred Stock owned prior to Conversion:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Number of shares of Preferred Stock to be Converted:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 38%">Stated Value of shares of Preferred Stock to be Converted:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 33%">Number of shares of Common Stock to be Issued:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Applicable Conversion Price:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 42%">Number of shares of Preferred Stock subsequent to Conversion:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">Address for Delivery: ______________________</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>or</U></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">DWAC Instructions:</P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Broker no: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Account no: &nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[HOLDER]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>tm2221834d1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 4.3</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">KIORA PHARMACEUTICALS,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">VSTOCK TRANSFER, LLC, as&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant Agency Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of July&nbsp;22, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>WARRANT AGENCY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WARRANT AGENCY AGREEMENT,
dated as of July&nbsp;22, 2022 (&ldquo;<U>Agreement</U>&rdquo;), by and between Kiora Pharmaceuticals,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and VStock Transfer, LLC, a New York limited liability trust company (&ldquo;<U>VStock</U>&rdquo;
or the &ldquo;<U>Warrant Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, pursuant to an offering
by the Company of Warrants (as defined below), the Company wishes to issue Warrants in book entry form entitling the respective holders
of the Warrants (the &ldquo;<U>Holders</U>&rdquo;, which term shall include a Holder&rsquo;s transferees, successors and assigns and &ldquo;Holder&rdquo;
shall include, if the Warrants are held in &ldquo;street name&rdquo;, a Participant (as defined below) or a designee appointed by such
Participant) to purchase an aggregate of up to 60,191,394 shares of Common Stock underlying the Warrants (as defined below) upon the terms
and subject to the conditions hereinafter set forth (the &ldquo;<U>Offering</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the Company wishes
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to act on behalf of the Company, in connection with
the issuance, registration, transfer, exchange, exercise and replacement of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NOW, THEREFORE, in consideration
of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;1. <U>Certain
Definitions</U>. For purposes of this Agreement, the following terms have the meanings indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&ldquo;<U>Affiliate</U>&rdquo;
has the meaning ascribed to it in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which the Nasdaq Stock Market is authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&ldquo;<U>Class&nbsp;A
Warrants</U>&rdquo; means Common Stock Purchase Warrants of the Company with a term of exercise of one (1)&nbsp;year following the Initial
Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&ldquo;<U>Class&nbsp;B
Warrants</U>&rdquo; means Common Stock Purchase Warrants of the Company with a term of exercise of five (5)&nbsp;years following the Initial
Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&ldquo;<U>Close of
Business</U>&rdquo; on any given date means 5:00 p.m., New York City time, on such date; <U>provided</U>, <U>however</U>, that if such
date is not a Business Day, it means 5:00 p.m., New York City time, on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, association, partnership, limited liability company, joint venture, trust, unincorporated organization,
government or political subdivision thereof or governmental agency or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp; &ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Class&nbsp;A Warrants and the Class&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp; &ldquo;<U>Warrant
Certificate</U>&rdquo; means a certificate in substantially the form attached as <U>Exhibit&nbsp;1-A</U> hereto (as it relates to the
Class&nbsp;A Warrants) or <U>Exhibit&nbsp;1-B</U> hereto (as it relates to the Class&nbsp;B Warrants), representing such number of Warrant
Shares (as defined below) as is indicated therein, provided that any reference to the delivery of a Warrant Certificate in this Agreement
shall include delivery of notice from the Depository or a Participant (each as defined below) of the transfer or exercise of the Warrant
in the form of a Global Warrant (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp; &ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock underlying the Warrants and issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other capitalized terms
used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;2. <U>Appointment
of Successor Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the express
terms or conditions hereof (and no implied terms and conditions), and the Warrant Agent hereby accepts such appointment. The Company may
from time to time appoint such Co-Warrant Agents as it may, in its sole discretion, deem necessary or desirable upon ten (10)&nbsp;calendar
days&rsquo; prior written notice to the Warrant Agent. The Warrant Agent shall have no duty to supervise, and shall in no event be liable
for, the acts or omissions of any such Co-Warrant Agent. In the event the Company appoints one or more co-Warrant Agents, the respective
duties of the Warrant Agent and any Co-Warrant Agent shall be as the Company shall reasonably determine, provided that such duties and
determination are consistent with the terms and provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;3. <U>Global
Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Warrants shall
be issuable in book entry form. All of the Warrants shall initially be represented by one or more Global Warrants (the &ldquo;<U>Global
Warrants</U>&rdquo; and, each, a &ldquo;<U>Global Warrant</U>&rdquo;), deposited with the Warrant Agent and registered in the name of
Cede&nbsp;&amp; Co., a nominee of The Depository Trust Company (the &ldquo;<U>Depository</U>&rdquo;), or as otherwise directed by the
Depository. Ownership of beneficial interests in the Warrants, shall be shown on, and the transfer of such ownership shall be effected
through, records maintained by (i)&nbsp;the Depository or its nominee for each Global Warrant or (ii)&nbsp;institutions that have accounts
with the Depository (such institution, with respect to a Warrant in its account, a &ldquo;<U>Participant</U>&rdquo;). For purposes of
Regulation SHO, a holder whose interest in a Global Warrant is a beneficial interest in certificate(s)&nbsp;representing such Warrant
held in book-entry form through the Depository shall be deemed to have exercised its interest in such Warrant upon instructing its broker
that is a Participant to exercise its interest in such Warrant, provided that in each such case payment of the applicable aggregate Exercise
Price (other than in the case of a cashless exercise) is delivered by such Participant within the earlier of (i)&nbsp;two trading days
and (ii)&nbsp;the number of trading days comprising the Standard Settlement Period, in each case following such instruction. As used herein,
 &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of trading days, on the Company&rsquo;s
primary trading market with respect to the Common Stock as in effect on the date of delivery of the Exercise Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;If the Depository
subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding
other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have
the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant
Agent for cancellation each Global Warrant, and the Company shall deliver to each Holder a Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp; A Holder has
the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate Request
Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such
Holder&rsquo;s Global Warrants for a Warrant Certificate, evidencing the same number of Warrants, which request shall be in the form
attached hereto as <U>Annex A</U> (a &ldquo;<U>Warrant Certificate Request Notice</U>&rdquo; and the date of delivery of such
Warrant Certificate Request Notice by the Holder, the &ldquo;<U>Warrant Certificate Request Notice Date</U>&rdquo; and the deemed
surrender upon delivery by the Holder of a number of Global Warrants for the same number of Warrants evidenced by a Warrant
Certificate, a &ldquo;<U>Warrant Exchange</U>&rdquo;), the Warrant Agent shall promptly effect the Warrant Exchange and shall
promptly instruct the Company to issue and deliver, at the expense of the Company, to the Holder a Warrant Certificate, for such
number of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Warrant Certificate shall be dated the
original issue date of the Warrants, shall be executed by manual signature by an authorized signatory of the Company, and shall be
in the form attached hereto as <U>Exhibit&nbsp;1-A</U> or <U>Exhibit&nbsp;1-B</U>, as the case may be. In connection with a Warrant
Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Warrant Certificate, to the Holder within
three (3)&nbsp;Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant
Certificate Request Notice (&ldquo;<U>Warrant Certificate Delivery Date</U>&rdquo;). Notwithstanding anything herein to the
contrary, the Company shall act as warrant agent with respect to any physical Warrant Certificate issued pursuant to this section
and VStock shall have no further obligations under this Agreement with respect to any physical Warrant Certificates issued under
this Agreement. If the Company fails for any reason to deliver to the Holder the Warrant Certificate subject to the Warrant
Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Warrant Certificate (based on the VWAP (as defined
in the Warrants) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day
after such Warrant Certificate Delivery Date until such Warrant Certificate is delivered or, prior to delivery of such Warrant
Certificate, the Holder rescinds such Warrant Exchange. In no event shall the Warrant Agent be liable for the Company&rsquo;s
failure to deliver the Warrant Certificate by the Warrant Certificate Delivery Date. The Company covenants and agrees that, upon the
date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be the holder of the Warrant Certificate,
as applicable, and, notwithstanding anything to the contrary set forth herein, the Warrant Certificate shall be deemed for all
purposes to contain all of the terms and conditions of the Warrants, evidenced by such Warrant Certificate, and the terms of this
Agreement, other than Sections 3(c)&nbsp;and 9 herein, shall not apply to the Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;4. <U>Form&nbsp;of
Warrant Certificates</U>. The Warrant Certificate, together with the form of election to purchase Common Stock (&ldquo;<U>Exercise Notice</U>&rdquo;)
and the form of assignment to be printed on the reverse thereof, shall be in the form of <U>Exhibit&nbsp;1-A</U> or <U>Exhibit&nbsp;1-B</U>,
as the case may be, hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;5. <U>Countersignature
and Registration</U>. The Warrant Certificates shall be executed on behalf of the Company by its Chief Executive Officer, Chief Financial
Officer or Vice President, either manually or by .pdf via email signature. In case any officer of the Company who shall have signed any
of the Warrant Certificates shall cease to be such officer of the Company, such Warrant Certificates, nevertheless, may be issued and
delivered with the same force and effect as though the Person who signed such Warrant Certificate had not ceased to be such officer of
the Company; and any Warrant Certificate may be signed on behalf of the Company by any Person who, at the actual date of the execution
of such Warrant Certificate, shall be a proper officer of the Company to sign such Warrant Certificate, although at the date of the execution
of this Agreement any such Person was not such an officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company will keep or
cause to be kept, at its office designated for such purposes, books for registration and transfer of the Warrant Certificates issued hereunder.
Such books shall show the names and addresses of the respective Holders of the Warrant Certificates, the number of warrants evidenced
on the face of each such Warrant Certificate and the date of each such Warrant Certificate. The Company will create a special account
for the issuance of Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;6. <U>Transfer,
Split Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates</U>. With respect
to the Global Warrant, subject to the provisions of the Warrant Certificate, and the last sentence of this first paragraph of Section&nbsp;6
and subject to applicable law, rules&nbsp;or regulations, or any &ldquo;stop transfer&rdquo; instructions the Company may give to the
Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close of Business on the Termination Date (as
such term is defined in the Warrant Certificate), any Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants
may be transferred, split up, combined or exchanged for another Warrant Certificate or Warrant Certificates or Global Warrant or Global
Warrants, entitling the Holder to purchase a like number of shares of Common Stock as the Warrant Certificate or Warrant Certificates
or Global Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring to transfer, split up, combine
or exchange any Warrant Certificate or Global Warrant shall make such request in writing delivered to the Warrant Agent or the Company,
as applicable, and shall surrender the Warrant Certificate or Warrant Certificates, together with the required form of assignment and
certificate duly executed and properly completed and such other documentation as the Warrant Agent or the Company, as applicable, may
reasonably request, to be transferred, split up, combined or exchanged at the office of the Warrant Agent designated for such purpose,
provided that no such surrender is applicable to the Holder of a Global Warrant. Any requested transfer of Warrants, whether in book-entry
form or certificate form, shall be accompanied by evidence of authority of the party making such request that may be reasonably required
by the Warrant Agent or the Company, as applicable. Thereupon the Company shall, subject to the last sentence of this first paragraph
of Section&nbsp;6, countersign and deliver to the Person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may
be, as so requested. The Company may require payment from the Holder of a sum sufficient to cover any tax or governmental charge that
may be imposed in connection with any transfer, split up, combination or exchange of Warrant Certificates. The Warrant Agent shall not
have any duty or obligation to take any action under any section of this Agreement that requires the payment of taxes and/or charges unless
and until it is satisfied that all such payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence shall
include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case of
loss, theft or destruction, of indemnity or security reasonably acceptable to the Company, and satisfaction of any other reasonable requirements
established by Section&nbsp;8-405 of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company
of all reasonable expenses incidental thereto, and upon surrender to the Company and cancellation of the Warrant Certificate if mutilated,
the Company will make and deliver a new Warrant Certificate of like tenor to the Holder in lieu of the Warrant Certificate so lost, stolen,
destroyed or mutilated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;7. <U>Exercise
of Warrants; Exercise Price; Termination Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Warrants shall
be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable on the Termination Date (as such term
is defined in the Warrant Certificate). Subject to the foregoing and to Section&nbsp;7(b)&nbsp;below, the Holder of a Warrant may exercise
the Warrant, in whole or in part upon surrender of the Warrant Certificate, if required, with the properly completed and duly executed
Exercise Notice and payment of the Exercise Price (unless exercised via a cashless exercise), which may be made, at the option of the
Holder, by wire transfer or by certified or official bank check in United States dollars, to the Warrant Agent at the office of the Warrant
Agent designated for such purposes. In the case of the Holder of a Global Warrant, the Holder shall deliver the duly executed Exercise
Notice and the payment of the Exercise Price as described herein. Notwithstanding any other provision in this Agreement, a holder whose
interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the Depository (or another established
clearing corporation performing similar functions) shall effect exercises by delivering to the Depository (or such other clearing corporation,
as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that is required by the
Depository (or such other clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained by the Warrant
Agent in connection with the services provided under this Agreement will be in its name and that the Warrant Agent may receive investment
earnings in connection with the investment at Warrant Agent risk and for its benefit of funds held in those accounts from time to time.
Neither the Company nor the Holders will receive interest on any deposits or Exercise Price. No ink-original Exercise Notice shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Upon receipt of an
Exercise Notice for a Cashless Exercise, the Warrant Agent shall deliver a copy of the Exercise Notice to the Company and request from
the Company, and the Company shall promptly calculate and transmit to the Warrant Agent in writing, the number of Warrant Shares issuable
in connection with such Cashless Exercise. The Warrant Agent shall have no obligation under this Agreement to calculate, the number of
Warrant Shares issuable in connection with a Cashless Exercise, nor shall the Warrant Agent have any duty or obligation to investigate
or confirm whether the Company&rsquo;s determination of the number of Warrant Shares issuable upon such exercise, pursuant to this Section&nbsp;7,
is accurate or correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;Upon exercise of
the Warrant Certificate pursuant to Section&nbsp;2 of the Warrant Certificate, the Warrant Agent or the Company, as applicable, shall
cause the Warrant Shares underlying such Warrant Certificate, or Global Warrant, to be delivered to or upon the order of the Holder of
such Warrant Certificate, or Global Warrant, registered in such name or names as may be designated by such Holder, no later than the Warrant
Share Delivery Date (as such term is defined in the Warrant Certificate). If the Company is then a participant in the DWAC system of the
Depository and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B)&nbsp;the Warrant is being exercised via Cashless Exercise, then the certificates for Warrant Shares
shall be transmitted by the Warrant Agent to the Holder by crediting the account of the Holder&rsquo;s broker with the Depository through
its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Sections 2(d)(i)&nbsp;or
2(d)(iv)&nbsp;of the Warrant Certificate, such obligation shall be solely that of the Company and not that of the Warrant Agent. Notwithstanding
anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any Holder fails to duly deliver payment
to the Warrant Agent or the Company, as applicable, of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased
upon exercise of such Holder&rsquo;s Warrant as set forth in Section&nbsp;7(a)&nbsp;hereof by the Warrant Share Delivery Date, the Warrant
Agent or the Company, as applicable, will not be obligated to deliver such Warrant Shares (via DWAC or otherwise) until following receipt
of such payment, and the applicable Warrant Share Delivery Date shall be deemed extended by one day for each day (or part thereof) until
such payment is delivered to the Warrant Agent or the Company, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;The Warrant Agent
shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company maintained with
the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise the Company via email
at the end of each day on which exercise notices are received, or funds for the exercise of any Warrant are received, of the amount so
deposited to its account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;In case the Holder
of any Warrant Certificate shall exercise fewer than all Warrants evidenced thereby, upon the request of the Holder, a new Warrant Certificate
evidencing the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued by the Company to the Holder
of such Warrant Certificate or to his duly authorized assigns in accordance with Section&nbsp;2(d)(ii)&nbsp;of the Warrant Certificate,
subject to the provisions of Section&nbsp;6 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;8. <U>Cancellation
and Destruction of Warrant Certificates</U>. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination
or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled
form, shall be canceled by it, and no Warrant Certificates shall be issued in lieu thereof except as expressly permitted by any of the
provisions of this Agreement. The Company shall cancel and retire any other Warrant Certificate purchased or acquired by the Company otherwise
than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at the written
request of the Company, destroy such canceled Warrant Certificates, and in such case shall deliver a certificate of destruction thereof
to the Company, subject to any applicable law, rule&nbsp;or regulation requiring the Warrant Agent to retain such canceled certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;9. <U>Certain
Representations; Reservation and Availability of Shares of Common Stock or Cash</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;This Agreement has
been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery hereof by the Warrant
Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms,
and the Warrants have been duly authorized, executed and issued by the Company and, assuming due execution thereof by the Warrant Agent
pursuant hereto and payment therefor by the Holders, constitute valid and legally binding obligations of the Company enforceable against
the Company in accordance with their terms and entitled to the benefits hereof; in each case except as enforceability may be limited by
bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors&rsquo; rights generally or
by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;As of the date hereof,
the authorized capital stock of the Company consists of (i)&nbsp;50,000,000 shares of Common Stock, of which 13,067,426 shares of Common
Stock are issued and outstanding, and 6,312,721 shares of Common Stock are reserved for issuance upon exercise of warrants, (ii)&nbsp;10,000,000
shares of preferred stock, 7.3735 of which are issued and outstanding and 2,089 shares of Common Stock are reserved for issuance upon
conversion of the preferred stock; and (iii)&nbsp;806,005 shares of Common Stock are authorized for issuance to employees, consultants
and directors pursuant to the Company&rsquo;s stock plan, under which options to purchase 522,066 shares are issued and outstanding. There
are no other outstanding obligations, warrants, options or other rights to subscribe for or purchase from the Company any class of capital
stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;The Company covenants
and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common Stock or its authorized
and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of Common Stock that will be
sufficient to permit the exercise in full of all outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;The Warrant Agent
will create a special account for the issuance of Common Stock upon the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;The Company further
covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which may be payable
in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon exercise of the
Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may be payable in respect of any transfer
involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for Common Stock in a name other
than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue or deliver any certificate
for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall have been paid (any such
tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender) or until it has been established
to the Company&rsquo;s and the Warrant Agent&rsquo;s reasonable satisfaction that no such tax or governmental charge is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;10. <U>Common
Stock Record Date</U>. Each Person in whose name any certificate for shares of Common Stock is issued (or to whose broker&rsquo;s account
is credited shares of Common Stock through the DWAC system) upon the exercise of Warrants shall for all purposes be deemed to have become
the holder of record for the Common Stock represented thereby on, and such certificate shall be dated, the date on which submission of
the Exercise Notice was made, provided that the Warrant Certificate evidencing such Warrant was duly surrendered (but only if required
herein) and payment of the Exercise Price (and any applicable transfer taxes) was received on or prior to the Warrant Share Delivery Date;
<U>provided</U>, <U>however</U>, that, if the date of submission of the Exercise Notice is a date upon which the Common Stock transfer
books of the Company are closed, such Person shall be deemed to have become the record holder of such shares on, and such certificate
shall be dated, the next succeeding day on which the Common Stock transfer books of the Company are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;11. <U>Adjustment
of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants</U>. The Exercise Price, the number of shares covered
by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section&nbsp;3 of the
Warrant Certificate. In the event that at any time, as a result of an adjustment made pursuant to Section&nbsp;3 of the Warrant Certificate,
the Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than
shares of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment
from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained
in Section&nbsp;3 of the Warrant Certificate, and the provisions of Sections 7, 9 and 13 of this Agreement with respect to the shares
of Common Stock shall apply on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment
made to the Exercise Price pursuant to the Warrant Certificate shall evidence the right to purchase, at the adjusted Exercise Price, the
number of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment
as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;12. <U>Certification
of Adjusted Exercise Price or Number of Shares of Common Stock</U>. Whenever the Exercise Price or the number of shares of Common
Stock issuable upon the exercise of each Warrant Certificate is adjusted as provided in Section&nbsp;11 or 13, the Company shall
(a)&nbsp;promptly prepare a certificate setting forth the Exercise Price of each Warrant Certificate, as so adjusted, and a brief,
reasonably detailed statement of the facts accounting for such adjustment, (b)&nbsp;promptly file with the Warrant Agent and with
each transfer agent for the Common Stock a copy of such certificate and (c)&nbsp;instruct the Warrant Agent, at the Company&rsquo;s
expense, to send a brief summary thereof to each Holder of a Warrant Certificate. The Warrant Agent shall be fully protected in
relying on such certificate and on any adjustment or statement therein contained and shall have no duty or liability with respect to
and shall not be deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such
certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;13. <U>Fractional
Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company shall
not issue fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any fractional Warrant
would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such fraction
to the nearest whole Warrant (rounded up).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;The Company shall
not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence fractional shares
of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed, the actual
issuance or distribution in respect thereof shall be made in accordance with Section&nbsp;2(d)(v)&nbsp;of the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14. <U>Concerning the Warrant Agent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company agrees
to pay to the Warrant Agent, pursuant to the fee schedule mutually agreed upon by the parties hereto and provided separately on the date
hereof, for all services rendered by it hereunder and, from time to time, its reasonable expenses and counsel fees and other disbursements
incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance
of its duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;The Company covenants
and agrees to indemnify and to hold the Warrant Agent harmless against any costs, expenses (including reasonable fees and expenses of
its legal counsel), losses or damages, which may be paid, incurred or suffered by or to which it may become subject, arising from or out
of, directly or indirectly, any claims or liability resulting from its actions or omissions as Warrant Agent pursuant hereto; provided,
that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect to, such costs, expenses,
losses and damages incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence, bad faith, or willful
misconduct (each as determined by a final non-appealable court of competent jurisdiction). Notwithstanding anything in this Agreement
to the contrary, any liability of the Warrant Agent under this Agreement will be limited to the amount of annual fees paid by the Company
to the Warrant Agent during the twelve (12) months immediately preceding the event for which recovery from the Warrant Agent is being
sought. The costs and expenses incurred by the Warrant Agent in enforcing this right of indemnification shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp; Upon the assertion
of a claim for which the Company may be required to indemnify the Warrant Agent, the Warrant Agent shall promptly notify the Company of
such assertion, and shall keep the other party reasonably advised with respect to material developments concerning such claim. However,
failure to give such notice shall not affect the Warrant Agent&rsquo;s right to and the Company&rsquo;s obligations for indemnification
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;Neither party to
this Agreement shall be liable to the other party for any consequential, indirect, punitive, special or incidental damages under any provisions
of this Agreement or for any consequential, indirect, punitive, special or incidental damages arising out of any act or failure to act
hereunder even if that party has been advised of or has foreseen the possibility of such damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;Notwithstanding anything
contained herein to the contrary, the rights and obligations of the parties set forth in this Section&nbsp;14 shall survive termination
of this Agreement, the expiration of the Warrants and/or the resignation, removal or replacement of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;15. <U>Purchase
or Consolidation or Change of Name of Warrant Agent</U>. Any Person into which the Warrant Agent or any successor Warrant Agent may be
merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Warrant Agent or any
successor Warrant Agent shall be party, or any Person succeeding to the stock transfer or other shareholder services business of the Warrant
Agent or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing
of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment
as a successor Warrant Agent under the provisions of Section&nbsp;17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;16. <U>Duties
of Warrant Agent</U>. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following express terms
and conditions (and no implied terms and conditions), by all of which the Company, by its acceptance hereof, shall be bound and shall
not assume any obligations or relationship of agency or trust with any of the Holders of the Warrants or any other Person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Warrant Agent
may consult with legal counsel selected by it (who may be legal counsel for the Company), and the opinion and advice of such counsel shall
be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in accordance with such
opinion or advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Whenever in the performance
of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established
by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein
specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer,
Chief Financial Officer or Vice President of the Company; and such certificate shall be full authorization and protection to the Warrant
Agent, and the Warrant Agent shall incur no liability for or in respect of any action taken, suffered or omitted to be taken by it under
the provisions of this Agreement in reliance upon such certificate. The Warrant Agent shall have no duty to act without such a certificate
as set forth in this Section&nbsp;16(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;Subject to the limitation
set forth in Section&nbsp;14, the Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct
(each as determined in a final, non-appealable judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;The Warrant Agent
shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Warrant Certificates
(including in the case of any notation in book-entry form to reflect ownership), except its countersignature thereof, by the Company or
be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;The Warrant Agent
shall not have any liability or be under any responsibility in respect of the validity of this Agreement or the execution and delivery
hereof (except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except
its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this
Agreement or in any Warrant Certificate; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change
in the number of shares of Common Stock required under the provisions of Section&nbsp;11 or 13 or responsible for the manner, method or
amount of any such change or adjustment or the ascertaining of the existence of facts that would require any such adjustment or change
(except with respect to the exercise of Warrants evidenced by Warrant Certificates after actual notice of any adjustment of the Exercise
Price); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any
shares of Common Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock
will, when issued, be duly authorized, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;Each party hereto
agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such
further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out or performing
by any party of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;The Warrant Agent
is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive Officer,
Chief Financial Officer or Vice President of the Company, and to apply to such officers for advice or instructions in connection with
its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in
good faith in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without gross negligence,
bad faith or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;The Warrant
Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other
securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract
with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement.
Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other Person. In the
event that the Warrant Agent seeks to exercise a Warrant, and provides the Company with (i)&nbsp;an opinion of counsel to the effect
that a public sale or transfer of the Common Stock issuable upon exercise of the Warrant may be made without registration under the
1933 Act and such sale or transfer is effected or (ii)&nbsp;the Purchaser provides reasonable assurances that the Securities can be
sold pursuant to an effective registration statement under the Securities Act of 1933, as amended, Rule&nbsp;144,
Section&nbsp;4(a)(1), or other applicable exemption, the Company shall permit the transfer, and, in the case of the Common Stock
issuable upon exercise of the Warrant, promptly instruct its transfer agent to issue one or more certificates, free from restrictive
legend, in such name and in such denominations as specified by the Holder. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the Holder by vitiating the intent and purpose of the transactions contemplated
hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this
Section&nbsp;16(h)&nbsp;may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions
of this Section, that the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any
breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;The Warrant Agent
may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through
its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any
such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence
or bad faith in the selection and continued employment thereof (which gross negligence and bad faith must be determined by a final, non-appealable
judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;The Warrant Agent
shall not be obligated to expend or risk its own funds or to take any action that it believes would expose or subject it to expense or
liability or to a risk of incurring expense or liability, unless it has been furnished with assurances of repayment or indemnity satisfactory
to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)&nbsp;The Warrant Agent shall not be liable
or responsible for any failure of the Company to comply with any of its obligations relating to any registration statement filed with
the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(l)&nbsp;The Warrant Agent may rely on and be fully
authorized and protected in acting or failing to act upon (a)&nbsp;any guaranty of signature by an &ldquo;eligible guarantor institution&rdquo;
that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &ldquo;signature guarantee program&rdquo;
or insurance program in addition to, or in substitution for, the foregoing; or (b)&nbsp;any law, act, regulation or any interpretation
of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m)&nbsp;In the event the Warrant Agent believes
any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document
received by the Warrant Agent hereunder, the Warrant Agent, may, in its sole discretion, refrain from taking any action, and shall be
fully protected and shall not be liable in any way to Company, the holder of any Warrant or any other Person for refraining from taking
such action, unless the Warrant Agent receives written instructions signed by the Company which eliminates such ambiguity or uncertainty
to the satisfaction of Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n)&nbsp;This Section&nbsp;16 shall survive the
expiration of the Warrants, the termination of this Agreement and the resignation, replacement or removal of the Warrant Agent. The costs
and expenses incurred in enforcing this right of indemnification shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;17. <U>Change
of Warrant Agent</U>. The Warrant Agent may resign and be discharged from its duties under this Agreement upon thirty (30) days&rsquo;
notice in writing sent to the Company and, in the event that the Warrant Agent or one of its affiliates is not also the transfer agent
for the Company, to each transfer agent of the Common Stock. In the event the transfer agency relationship in effect between the Company
and the Warrant Agent terminates, the Warrant Agent will be deemed to have resigned automatically and be discharged from its duties under
this Agreement as of the effective date of such termination, and the Company shall be responsible for sending any required notice thereunder.
The Company may remove the Warrant Agent or any successor Warrant Agent upon thirty (30) days&rsquo; notice in writing, sent to the Warrant
Agent or successor Warrant Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the Warrant
Certificates. If the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint
a successor to the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after such removal
or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder
of a Warrant Certificate (who shall, with such notice, submit this Warrant Certificate for inspection by the Company), then the Holder
of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent, provided that,
for purposes of this Agreement, the Company shall be deemed to be the Warrant Agent until a new warrant agent is appointed. Any successor
Warrant Agent, whether appointed by the Company or by such a court, shall be a Person, other than a natural person, organized and doing
business under the laws of the United States or of a state thereof, in good standing, which is authorized under such laws to exercise
stock transfer powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment
as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested
with the same powers, rights, duties and responsibilities as if it had been originally named as Warrant Agent without further act or deed;
but the predecessor Warrant Agent shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder,
and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose but such predecessor Warrant Agent shall
not be required to make any additional expenditure (without prompt reimbursement by the Company) or assume any additional liability in
connection with the foregoing. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing
with the predecessor Warrant Agent and each transfer agent of the Common Stock and mail a notice thereof in writing to the Holders of
the Warrant Certificates. However, failure to give any notice provided for in this Section&nbsp;17, or any defect therein, shall not affect
the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;18. <U>Issuance
of New Warrant Certificates</U>. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company
may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect
any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property
purchasable under the several Warrant Certificates made in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;19. <U>Notices</U>.
Notices or demands authorized by this Agreement to be given or made (i)&nbsp;by the Warrant Agent or by the Holder of any Warrant Certificate
to or on the Company, (ii)&nbsp;by the Company or by the Holder of any Warrant Certificate to or on the Warrant Agent or (iii)&nbsp;by
the Company or the Warrant Agent to the Holder of any Warrant Certificate, shall be deemed given when in writing (a)&nbsp;on the date
delivered, if delivered personally, (b)&nbsp;on the first Business Day following the deposit thereof with Federal Express or another recognized
overnight courier, if sent by Federal Express or another recognized overnight courier, (c)&nbsp;on the fourth Business Day following the
mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt requested), and (d)&nbsp;the time of transmission,
if such notice or communication is delivered via e-mail attachment at or prior to 5:30 p.m.&nbsp;(New York City time) on a Business Day
and (e)&nbsp;the next Business Day after the date of transmission, if such notice or communication is delivered via e-mail attachment
on a day that is not a Business Day or later than 5:30 p.m.&nbsp;(New York City time) on any Business Day, in each case to the parties
at the following addresses (or at such other address for a party as shall be specified by like notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">If to the Company, to:</TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in">Kiora Pharmaceuticals,&nbsp;Inc.&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">1371 East 2100 South, Suite&nbsp;200&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Salt Lake City, UT 84105&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">E-mail: bstrem@kiorapharma.com&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Attn: Brian Strem</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">With a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Burns&nbsp;&amp; Levinson LLP&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">125 High Street&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Boston, MA 02110&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">E-mail: rpetitt@burnslev.com&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Attn: Robert Petitt</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">If to the Warrant Agent, to:</TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">VStock Transfer, LLC&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">18 Lafayette Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">Woodmere, NY 11598&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">E-mail: young@vstocktransfer.com&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">Attn: &nbsp;&nbsp;&nbsp;&nbsp;Young Kim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For any notice delivered by email to be deemed
given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the next Business Day following
such email, unless the recipient of such email has acknowledged via return email receipt of such email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;If to the Holder
of any Warrant Certificate, to the address of such Holder as shown on the registry books of the Company. Any notice required to be delivered
by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding any other provision
of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice shall be sufficiently
given if given to the Depository (or its designee) pursuant to the procedures of the Depository or its designee. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;20. <U>Supplements
and Amendments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company and the
Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global Warrants in order
to (i)&nbsp;add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants, (ii)&nbsp;to surrender
any rights or power reserved to or conferred upon the Company in this Agreement, (iii)&nbsp;to <FONT STYLE="background-color: white">cure
any ambiguity, (iv)&nbsp;to correct or supplement any provision contained herein which may be defective or inconsistent with any other
provisions herein, or (v)&nbsp;to make any other provisions with regard to matters or questions arising hereunder which the Company and
the Warrant Agent may deem necessary or desirable</FONT>, provided that such addition, correction or surrender shall not adversely affect
the interests of the Holders of the Global Warrants or Warrant Certificates in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;In addition to the
foregoing, with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority of the shares
of Common Stock issuable thereunder, the Company and the Warrant Agent may modify this Agreement for the purpose of adding any provisions
to or changing in any manner or eliminating any of the provisions of this Agreement or modifying in any manner the rights of the Holders
of the Global Warrants; <U>provided</U>, <U>however</U>, that that (i)&nbsp;if any amendment, modification or waiver disproportionately
and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall
also be required and (ii)&nbsp;no modification of the terms (including but not limited to the adjustments described in Section&nbsp;11)
upon which the Warrants are exercisable or reducing the percentage required for consent to modification of this Agreement may be made
without the consent of the Holder of each outstanding warrant certificate affected thereby; <U>provided further</U>, <U>however</U>, that
no amendment hereunder shall affect any terms of any Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the
Warrant Agent&rsquo;s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized
officer of the Company that states that the proposed amendment complies with the terms of this Section&nbsp;20. No supplement or amendment
to this Agreement shall be effective unless duly executed by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;21. <U>Successors</U>.
All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;22. <U>Benefits
of this Agreement</U>. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant
Certificates and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for
the sole and exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;23. <U>Governing
Law; Jurisdiction</U>. This Agreement and each Warrant Certificate issued hereunder shall be governed by, and construed in accordance
with, the laws of the State of New York without giving effect to the conflicts of law principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the
courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to
such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenience forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;24. <U>Counterparts</U>.
This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original,
and all such counterparts shall together constitute but one and the same instrument. A signature to this Agreement transmitted electronically
shall have the same authority, effect and enforceability as an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;25. <U>Captions</U>.
The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning or
construction of any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the
remaining provisions of this Agreement; provided, however, that if such prohibited and invalid provision shall adversely affect the
rights, immunities, liabilities, duties or obligations of the Warrant Agent, the Warrant Agent shall be entitled to resign
immediately upon written notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;27. <U>Conflicts</U>.
To the extent any provision of this Agreement conflicts with the express provisions of the Warrant Certificate, the provisions of the
Warrant Certificate shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;28. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Force
Majeure</U>. Notwithstanding anything to the contrary contained herein, the Warrant Agent will not be liable for any delays or
failures in performance resulting from acts beyond its reasonable control, including, without limitation, acts of God, terrorist
acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to
power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil
unrest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The parties hereto acknowledge that there are no agreements or understandings, written or oral, between them with
respect to matters contemplated hereunder other than as set forth herein and the Warrant Certificates, that this Agreement and the
Warrant Certificates contain the entire agreement between them with respect to the subject matter hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;30. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees;
Expenses</U>. As consideration for the services provided by VStock (the &ldquo;<U>Services</U>&rdquo;), the Company shall pay to
VStock the fees set forth on <U>Schedule 1</U> hereto (the &ldquo;<U>Fees</U>&rdquo;). If the Company requests that VStock provide
additional services not contemplated hereby, the Company shall pay to VStock fees for such services at VStock&rsquo;s reasonable and
customary rates, such fees to be governed by the terms of a separate agreement to be mutually agreed to and entered into by the
Parties at such time (the &ldquo;<U>Additional Service Fee</U>&rdquo;; together with the Fees, the &ldquo;<U>Service
Fees</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall reimburse VStock for all reasonable and documented expenses incurred by VStock (including, without limitation, reasonable
and documented fees and disbursements of counsel) in connection with the Services (the &ldquo;<U>Expenses</U>&rdquo;); <U>provided</U>,
<U>however</U>, that VStock reserves the right to request advance payment for any out-of-pocket expenses. The Company agrees to pay all
Service Fees and Expenses within thirty (30) days following receipt of an invoice from VStock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees and acknowledges that VStock may adjust the Service Fees annually, on or about each anniversary date of this Agreement,
by the annual percentage of change in the latest Consumer Price Index of All Urban Consumers United States City Average, as published
by the U.S. Department of Labor, Bureau of Labor Statistics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of this Agreement for any reason, VStock shall assist the Company with the transfer of records of the Company held by VStock.
VStock shall be entitled to reasonable additional compensation and reimbursement of any Expenses for the preparation and delivery of such
records to the successor agent or to the Company, and for maintaining records and/or Stock Certificates that are received after the termination
of this Agreement (the &ldquo;<U>Record Transfer Services</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KIORA
    PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian Strem&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Strem&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VSTOCK
    TRANSFER, LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Young D. Kim&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Young D. Kim&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.75in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.75in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex A: Form&nbsp;of Warrant Certificate Request
Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To: VStock Transfer, LLC, as Warrant
Agent for Kiora Pharmaceuticals,&nbsp;Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The undersigned Holder of Common Stock
Purchase Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Name of Holder of Warrants in form of Global Warrants: ___________________________</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Number of Warrants in name of Holder in form of Global Warrants: ___________________</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>Number of Warrants for which Warrant Certificate shall be issued: __________________</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate,
if any: ___________</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>Warrant Certificate shall be delivered to the following address:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The undersigned hereby acknowledges
and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered
the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="text-transform: uppercase">[SIGNATURE OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Signature of Authorized Signatory of Investing Entity</I>:
______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Date: _______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>







<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2221834d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="text-align: justify; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #26282A"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #26282A"><B>Kiora Pharmaceuticals Announces
Pricing of $5.2 Million Underwritten Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529; background-color: white">Salt
Lake City, Utah--(Newsfile Corp. - July&nbsp;22, 2022) - Kiora Pharmaceuticals,&nbsp;Inc. (NASDAQ: KPRX), (&quot;Kiora&quot; or the &quot;Company&quot;)
today announced </FONT><FONT STYLE="background-color: white">the pricing of an underwritten public offering for gross proceeds of approximately
$5.2 million prior to deducting underwriting discounts and commissions and offering expenses.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
offering is comprised of (i)&nbsp;19,770,172 shares of common stock, (ii)&nbsp;1,280 shares of Series&nbsp;E convertible preferred stock,
(iii)&nbsp;26,170,172 Class&nbsp;A Warrants with an exercise price of $0.20 per share and a term of one year following the initial exercise
date, and (iv)&nbsp;26,170,172 Class&nbsp;B Warrants with an exercise price of $0.20 per share and a term of five years following the
initial exercise date. The price per share of common stock, Class&nbsp;A Warrant and Class&nbsp;B Warrant is $0.20. The price per share
of series E convertible preferred stock, Class&nbsp;A Warrant to purchase 5,000 shares of common stock and Class&nbsp;B Warrant to purchase
5,000 shares of common stock is $1,000.00. The warrants issued in this transaction are fixed priced and do not contain any variable pricing
features.</FONT> T<FONT STYLE="background-color: white">he warrants will be exercisable beginning on the effective date of a reverse stock
split in an amount sufficient to permit the exercise in full of the warrants, contingent upon stockholder approval of such reverse stock
split and of the exercisability of the warrants. The shareholder meetings will be held on or before September&nbsp;23, 2022. The closing
of the offering is expected to take place on or about July&nbsp;26, 2022, subject to the satisfaction or waiver of customary closing conditions.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladenburg Thalmann&nbsp;&amp; Co. Inc. is
acting as sole book-running manager in connection with this offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">In addition,
the Company has granted the underwriter a 45-day option to purchase up to 3,925,525 additional shares of common stock, additional Class&nbsp;A
Warrants to purchase up to 3,925,525 shares of common stock and additional Class&nbsp;B Warrants to purchase up to 3,925,525 shares of
common stock, solely to cover over-allotments, if any, at</FONT>&nbsp;the public offering price per share of common stock, Class&nbsp;A
Warrant and Class&nbsp;B Warrant<FONT STYLE="background-color: white">, less the underwriting discounts and commissions. The securities
were offered pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-264641), which was declared effective by the United
States Securities and Exchange Commission (&#8220;SEC&#8221;) on July&nbsp;21, 2022.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">This
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction. The offering is being made solely by means of a prospectus. A preliminary prospectus relating to the proposed
offering was filed with the SEC on July&nbsp;21, 2022 and is available on the SEC&#8217;s website located at http://www.sec.gov. A final
prospectus relating to this offering will be filed by Kiora with the SEC. When available, copies of the final prospectus can be obtained
at the SEC&#8217;s website at http://www.sec.gov or from Ladenburg Thalmann&nbsp;&amp; Co. Inc., Prospectus Department, 640 Fifth Avenue,
4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>About Kiora Pharmaceuticals</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">Kiora Pharmaceuticals is a
clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being
developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients
with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid
Arthritis (&quot;OPRA&quot;). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate
Dehydrogenase (&quot;DHODH&quot;) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism
(blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues
associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer
hyaluronic acid, designed to accelerate corneal wound healing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529">In
addition to news releases and SEC filings, we expect to post information on our website,&nbsp;</FONT><U>www.kiorapharma.com<FONT STYLE="color: #212529">,</FONT></U><FONT STYLE="color: #212529">&nbsp;and
social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to
visit our website and/or subscribe to email alerts.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">Some
of the statements in this press release are &quot;forward-looking&quot; and are made pursuant to the safe harbor provision of the
Private Securities Litigation Reform Act of 1995. These &quot;forward-looking&quot; statements include statements relating to, among
other things, Kiora&#8217;s expectations with respect to completing the public offering in a timely manner or at all, the
anticipated use of the net proceeds of the offering, the development and commercialization efforts and other regulatory or marketing
approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success
thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks
and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among
other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors
described under the heading &quot;Risk Factors&quot; contained in Kiora's Amendment No.&nbsp;1 to Annual Report on Form&nbsp;10-K/A
filed with the SEC on July&nbsp;7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by
factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of
this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such
statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances
on which any such statement is based, except as required by law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>Investor Contact</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529">Francina
Agosti, PhD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529">(617) 546-0742</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>fagosti@reportablenews.com</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>tm2221834d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #26282A"><B>Kiora Pharmaceuticals Announces
Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529; background-color: white">Salt
Lake City, Utah--(Newsfile Corp. - July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (&quot;Kiora&quot; or the &quot;Company&quot;)
today announced </FONT><FONT STYLE="background-color: white">the closing of an underwritten public offering for gross proceeds of approximately
$6.0 million, which includes full exercise of the underwriter&#8217;s over-allotment option to purchase additional shares and warrants,
prior to deducting underwriting discounts and commissions and offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
offering was comprised of (i) 23,695,697 shares of common stock, (ii) 1,280 shares of Series E convertible preferred stock, (iii) 30,095,697
Class A Warrants with an exercise price of $0.20 per share and a term of one year following the initial exercise date, and (iv) 30,095,697
Class B Warrants with an exercise price of $0.20 per share and a term of five years following the initial exercise date. The price per
share of common stock, Class A Warrant and Class B Warrant was $0.20. The price per share of series E convertible preferred stock, Class
A Warrant to purchase 5,000 shares of common stock and Class B Warrant to purchase 5,000 shares of common stock was $1,000.00. The warrants
issued in this transaction are fixed priced and do not contain any variable pricing features.</FONT> T<FONT STYLE="background-color: white">he
warrants will be exercisable beginning on the effective date of a reverse stock split in an amount sufficient to permit the exercise in
full of the warrants, contingent upon stockholder approval of such reverse stock split and of the exercisability of the warrants. The
shareholder meetings will be held on or before September 23, 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladenburg Thalmann &amp; Co. Inc. acted as
sole book-running manager in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
securities issued at closing include 3,925,525 shares of common stock, Class A Warrants to purchase up to 3,925,525 shares of common stock
and additional Class B Warrants to purchase up to 3,925,525 shares of common stock, issued upon the full exercise of the over-allotment
option. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-264641), which was declared effective
by the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on July 21, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">This
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction. A final prospectus relating to this offering was filed by Kiora with the SEC on July 25, 2022. Copies of the
final prospectus are available on the SEC&#8217;s website at http://www.sec.gov or can be obtained from Ladenburg Thalmann &amp; Co. Inc.,
Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>About Kiora Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">Kiora Pharmaceuticals is a
clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being
developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients
with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid
Arthritis (&quot;OPRA&quot;). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate
Dehydrogenase (&quot;DHODH&quot;) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism
(blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues
associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer
hyaluronic acid, designed to accelerate corneal wound healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to news
releases and SEC filings, we expect to post information on our website, <U>www.kiorapharma.com,</U> and social media accounts that could
be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe
to email alerts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">Some of the statements in
this press release are &quot;forward-looking&quot; and are made pursuant to the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These &quot;forward-looking&quot; statements include statements relating to, among other things, the anticipated use
of the net proceeds of the offering, the development and commercialization efforts and other regulatory or marketing approval efforts
pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals
or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause
results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct
clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &quot;Risk Factors&quot;
contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora's other
public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements
in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the
events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #212529">Francina Agosti,
PhD<BR>
(617) 546-0742<BR>
</FONT><U>fagosti@reportablenews.com</U></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>kprx-20220722.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaKAabOdzZR+mYkxtmB6bSkqHyMnXonNyiNOQsFmMZsL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20220722" elementFormDefault="qualified" targetNamespace="http://eyegatepharma.com/20220722">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://eyegatepharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20220722_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20220722_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>kprx-20220722_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>kprx-20220722_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyegatepharma.com/role/Cover" xlink:href="kprx-20220722.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://eyegatepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140494651253056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1371 East 2100 South<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-9043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2221834d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20220722.xsd" xlink:type="simple"/>
    <context id="From2022-07-22to2022-07-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-07-22</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-07-22to2022-07-22">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-07-22to2022-07-22">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-07-22to2022-07-22">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2022-07-22to2022-07-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-07-22to2022-07-22">2022-07-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-07-22to2022-07-22">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-07-22to2022-07-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-07-22to2022-07-22">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-07-22to2022-07-22">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-07-22to2022-07-22">1371 East 2100 South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-07-22to2022-07-22">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-07-22to2022-07-22">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-07-22to2022-07-22">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-22to2022-07-22">84105</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2022-07-22to2022-07-22">84105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-07-22to2022-07-22">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-07-22to2022-07-22">788-9043</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-07-22to2022-07-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-07-22to2022-07-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-07-22to2022-07-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-07-22to2022-07-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-07-22to2022-07-22">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-07-22to2022-07-22">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-07-22to2022-07-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-07-22to2022-07-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #A@_I4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .&#^E0_UN^)[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .&#^E297)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ X8/Z5)U^
MV4"#!   NQ$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .&#^E2?H!OPL0(  .(,   -
M  "  <<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ X8/Z5)>*NQS
M$P(   L              ( !HP\  %]R96QS+RYR96QS4$L! A0#%     @
MX8/Z5*K$(A8S 0  (@(   \              ( !C!   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( .&#^E0D'INBK0   /@!   :              "
M >P1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .&#
M^E1ED'F2&0$  ,\#   3              "  =$2  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  !L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2221834d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2221834d1_8k.htm">tm2221834d1_8k.htm</File>
    <File>kprx-20220722.xsd</File>
    <File>kprx-20220722_lab.xml</File>
    <File>kprx-20220722_pre.xml</File>
    <File>tm2221834d1_ex1-1.htm</File>
    <File>tm2221834d1_ex3-1.htm</File>
    <File>tm2221834d1_ex4-3.htm</File>
    <File>tm2221834d1_ex99-1.htm</File>
    <File>tm2221834d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2221834d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2221834d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20220722_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20220722_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20220722.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "KPRX",
   "nsuri": "http://eyegatepharma.com/20220722",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2221834d1_8k.htm",
      "contextRef": "From2022-07-22to2022-07-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2221834d1_8k.htm",
      "contextRef": "From2022-07-22to2022-07-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-22-082802-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-082802-xbrl.zip
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MIR& 6>.41-,%Q0I@#CY5J?7^:5D\DC25]PPP[6]8;&+7Q,"&=69,95#4@/9
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M(4"1"$+M*-\PS6G$^#-K/"XQ8QO1&.YF+(9'+#U1;L$:5(0V7ITA 4$VQ">
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ME(L<\9N'!VOOWR5V!4:_804(K P"E%Y[.C B8!PU(E 9@HH8_^C,LVQ#^)L
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M,+7&8AVX7X;3QV7W\B&.7TF:_D39*UT0G#%*XO)ZB^WN4K?>[5,W/;;;#]X
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M&P.?,'WBF^<\VMUR%A$BG];*ZI:K[QK=P&BWW+RI2&VB!H4&Q-I;_ (4[K-
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MK-U$@<OLSR7N=2$VQ'I&C8EC9I_+XY,,E":LF?U<3M/!_"6.6H@Q&9$ 8\\
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M#Q2:BA2:"X^ARF(E(B^W0 OMG?=Z:8Z3>^6^/^W-BGVS^J3"DX[7_80H798
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MPS[,)2<D:I2&<<+( ^A"/J,5#4^!(E?P&*@GYL"$1=$(7/C$K7(LA6Z#.N7
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M'V'_A85];GB?5]+G"\V=0IY_=@%_HDQR'4*F49B 2D_=$(_95!07)K!G.<,
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ML)P+;U3[J37\.2TB..3P]XKHZ*54/=_/+Z[LR>(\?Y><4#_X>=SDEW.OU"+
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MR1Q+7 ,Q5W@%#%NPMX(1I!QBTC0)9A4EF;A;[=!J*V#E<.#;_N'E[O$LR(W
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M^0KW&&F^MGKC?XOQY_=^%#B[[446T)R[-0RM(?6G[XM9]A.*?TP/]=T"!!9
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M<EQG4V;6E?K]8V1>$%@AT50(QE'^T+_H9*:KM&N8GYV\P#@A?%3[@E5>HSO
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MN+Y2,Q+HD\1BZ JQ"8BF1:W-"&U-.""T'R9T-HT%:XR.S:TKI#*0SHHUQS3
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ML]HP+F&034'L$'FE<-THDKZMV;V7)IQ&<US\!9)^.Z38S0-%[,Q$[+4;D#K
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MG.FC(E@A)ZEK;T!I2]<$)41.XA5:>N@F?-Y88"0VBD-1$]MX3/:H&H6.VM,
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M!GG>]OK490?-LSP.4-/B)X'6M=L63F\UF6$5[;\R&(7FGU=WQJJNC DAX,#
MTJ![H )B(#*[Y"J57(MW2=#OE#= MP %0RR] [*&0)V)<?BJ=!RM57Z<2:MY
M.I\E&"()C5AH;#B,HZA+6)Q+8@<0[/KRZ1"VD5::D'I.QQ/K=)F+Z":W?6?3
M!5\UP$1LGXER1S9X).$-&0/YK4U_<X)JSI4=[@P:3X'>\ 7C4=FK.6RVH_WZ
M]J+!H<&K+7$EP&XQMJZA&<?KK 7G54NUWV[!(!R6&]JV"V64<4'*B]3&0N>_
M1UY$%3<23H6")PG!8%PRK73G57 *2+\@D>>T)TJ;*^4W0U&5+_+."^B*#R(
M&K0!T:I.$3=3X2F)-+R"M3;9=&O80$FZN:CI>ITS3K[[H.S=X""MQY8X6DY9
M+K+S#X/5E>"60&>K*!DY!E@J3V:L)#^Q-N9 GMY67DRY=:*L-:JCQH7Q[F6M
MK,?M:"S7!,P\$<R$]N'%#;^])54'W2>ENH8NG?(*K&,Z:J;N8T#4W/^8NO,
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M%3P<?+5$XH))-@RFZ"VJL!&M)NS67!>'%P$N%;XTJRA(?4+4EM4$F"V<QC&
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M65',C471*7X!BALJ;>WQ5*:5]N5,EKQ&(.+D'78=[7ZMX?6YT"!Q>QR*KFR
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M:2U/UO6T:]5&@]>GY('*[=8FO@01W])#%6JPTZ=*E5EEIWNXDT#QQY'W4*=
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M;O\B!U^]:*MZR6%5+_2:P^HDD?@K&S@:Q\(?NE:-$Z_:WA*WA):;WN!?TVH
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M\E>5-9L\R+[>U,\PQC=D-*_<GR).-8Q&QBQ:"8.<3O4 Y>^*XHE!\GM!0(R
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MX*\X-1>+#.< 0?:&C+%=SDG7V>_@*]B<(%9,_KBK[F3XY(&-%=_6RC8U$KQ
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MJ^AVL.EU56*W"UM9A\W>L*AJ=YT2.>5A=.E<O#-VEYYLP"^<7O3HJ5:@GI[
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M)<>2ZBEM26/7BJ5:<M)\!.] $M'=X0S@2#&_OL\N<.11H60E31NWCB<3B4<
M^[[[[.)T]/KJV[,7[=;1ZY/1,7X*^G=T]>;J[.3%T6[XB6]WX]='+\^/?Q"7
M5S^<G?SUT<04_D ,^J475SI73KQ3"_'>Y++HA <=<:FLGCS"QGCR]G]'%_61
M7MWXKLSTM#@0/U;.Z\GR4.323C4>@- C,'7!QZWW/)2-C8-$_U!L)9:8S-@#
M\=5P?_C-</3HQ=?%V)6'_R&J5D]G_N<TCUZ^.+F9Z;'VXOGSWN!H]^7_K-A=
M;TJFO'HP-MZ;/#YK\I*HPBN[51MOM;%27,RDS66B*J\3F3DQ*@I3%8ER[=:%
MU8DNIL),Q)_W>D/QK<XR;0KQH4B575CMO2K$137.="+.)Q-P6$P_)[5NW?RK
M61G+Y'IJH9NT&QE8S+174.7I^;NKFN:*M\%P;_C\GEV7,O/MUIF\5N*5]LN.
M^.#EK-O= 3MNHC,\-;;LB:[X>Y4M@X3#84<,^\/A8SS=:KQ.6/>F2'IBY]WH
M\GCTCP/Q]N+]/Q]WQ,[7'ROC#WE?^%48*_Q,B?#IE<E+62S#A\?MEC>I7 H9
MO2$51[LDYJ:P=PI'QY9K[Y&%J)H^4P:?,=%G8!,K<(YSV&02I5+'NTI\NM&Y
M]"I;MEOL@GET01Q.W!N1JK1*/!VRHD ?4NT2\.4=:*=PF#S7SF%C^+PBK&Y*
M53CE>K5TOY</?4XN?.>JJYEJMU:ZTX[T"D,X11H5._IQD&+PO//L6;\S>#84
M#OZIV)AD MC->9-<PQGU:G%G^$V_L8X85RY\=X)=Q5Q9K\<9^9,"90MBX9!V
M"Z?4QPSW02_0?)5)%P\8B>^EM9+<8*']C/Q0W2B;@&5V3\6IK=\;]D6I;.""
M'40B\=B<OC6%$DLE+92>969!@I-SZP)^)K/5<>U6"C?M\.8=/;^7JY?_/E<3
M/0]LN4V^VJW;C GBJR>N9O79ZR-_9I5MFF/"VY@G^S.36P\G/Q&.;2GN-^-V
MJHCLLK+)3$*"O4Z_W[_#E>YFKW%"NW7O$23(@!;T^E&816T?)(T*G.H"RL4R
MCZ=.(MU@+VEPHF_P+8N>,B>I$87Q)*^7V(1\*N;2:AD$YWS8;DV4])5=)QUQ
M];#P:S*V0!X48U6;F0F,%6*]X)1;L),JA"J8G0<GX)0JK((EH%06O=UR908\
MQ*P*F5/&%*Z:3,"IBCJ$QV$%'U>[%)9/*M#'@;[!5(?E!GW:6I6U?F<F0V(.
MV7PN>9>KDMEV3D)V;I*38XTOEK>)!4.Q12.!7"DBOM;-3&4IJ0*%8JQ08A22
M2^E5/E8VAN>34$_#64EF'-LG4FHF.JH3B8>1H1%/);O,),4I'R['IO+-,KT?
MCNU SO&/V,>[B%OIM9M$_\'&A81M+/LC4CORMUW67) J4TT+O_C:="9358PK
M.X659(:#BL#0US(O#X&2>H+QC@9@E0$)2"><H8 PYKIKJQ 3V"BGT#:<%[HM
M5+ ")V".[=K<O2]5SP]+0F^0)]+@F:C Y-41. ID6H XQ":%"9ZO\!@%OWBZ
MUR4\:4I6>S.]5R5]?-)Y/MSK[ WW5L<C5=P%'QI+FM6CW5H5UOL(W%-)MA_<
M*-@/.K?=VF27G#%;TN+$<,#C?S!H9GRN.&]J@LAH :2/L1[H,HJ^!95_41%?
M*>3.,ODPHW=$I@#.-ZQZ+\J.V5DE%:VD7G*A;$RI5#$KZZI8I*DD3;5#:67/
M<!ZEBM1"R?74V#PP?-D=B)U3:HO>F5YX].3)D^YP_^G^TP&Z&S"*DK* "Z8J
MR20165>_\9)9_P!HI-)VZY)(.(1'S1US?W(#JZ)VD3]',= S??7-<-@_O#QY
MQ;\-#A\36XU4/X@5Y O/T0_M'RA) P#"EZS*% 51:D _8B:PYRM/6#=X"KF'
M4P0T0J.*. (P\<%10ENY6C>N$#\%%56J_EAM"1 Q G,R"^&.IV[3*R-&^Q$/
M7*I#2<"SX$V,4IA YQ9IRV>*A:F ,,84%)E< !*MV](-G\:CCQ6, %@5'G 0
M!9$:S. ,MT)'399"-#7QR%B%DI:J.KG QW,%=!I0'J"6(\12(1)'!+DSG>N"
M\,7Z&S*!Y#".\ 1?E<91A*Q(44#1,"*M"R4PU,FK[3' 403>Y%SJC %IA*$Q
M>@;/#H'-U-C!%T1FH H"S5[,O"\/=G<7BT4/VNA-S9QXGH#=C)SE#G8;%7L%
M^ *GT$08CC19[HGO9ZI8\T98M=0KMPCDFLI)X%PXTHP)R)-.I+]3F*U"D-4G
MUN3B8?BE(R[6Q(]5*2T7AX[8?]H7IWH"449S550*5?<I/IQFQL O*7)_,/9Z
M_1OBNC]XSJ!W*50.>8F_M61_RVI^>DC87W;B:HP2>5S'8]$1P_FM\[7MP\W?
MB=7/3'/;I\F4#P"',EW0YRZJ.RKL6!NODEF!$Z9+'B)1$D[1#V8(2@+P$4U0
M PA)?@K Q]"DS_&PD"+16_31 2E,@"MGGJ(+4 F@A"H+,M_;-^?=)_W!*F&V
M6Y$&LL364RQUD,C&3I1Z2@^-DPA/GG5(D2/3)A7 A2AG!E\AOR248"C\94!'
M)00K>/["-0"0#&5HKEVL*R42&"$^P"'*3;I F=(^S YVJ9.<JBZG.3QB7G!0
MJM!/JU!)@DB#ADCB$Q+1@_/ ] 7XP=-5]7P_4U4NO=%(;B/K9Y8%CV/B\XOW
MHS@*7BN@(,]:<T/UMH!)E<49,@.,S?.J,-T<AH(,QB[9D"X'U*V51\,#OH,Q
MW/<>Z]DRM<ADAC!9NW6L^#-H$#:(O!R_/C]^'9D)27U!.@\.-T9I@PI<T(CS
M75UT$P*Z,"%<R+"YR"K),L[0YO"HE%7,_"H1^>6*J@@$:I>W6SMCU*AK)ZY$
M0A $[H<"'B7GD_!$%Y-,YGF0-5EZ<XU:44.;Q["-0Q2&J0%A?O"CZM%"UR/.
ME!=.I_6@)N!0)R?*+\/DB5I:YPR"P-<E>!T6*/KK4LLZ6NO645%9-VI15]HU
M@XQ<:=A'\2;/3@%.@@_EM=L4-*6BHFBR)4BV6[.ES"IK$,E")CKM;,@G$ZB)
MU*/ HBT4-BXH:X@9?OT=V^K/+&_>>UM$W34L'JU&6BW48@65@WL0_ +.H4$7
MNAX5)U/<EQI'DSPR88QQ_%?9&J5T:KE#O?_P@K#*-?E%R3F;T,"]O'564.'#
M_4($0F"VW6+?1?"K5$MRD= L<LI,:O!,XLUC,ZB+.2=-^._WD*W (DL58_6<
M%H6)MP!.@H17"[I2LJR;,UU<JY0<G[ 9@I:RLFFW* '[IB[J?.NJL4NL!A,X
M-F(E.+'_,F9NC6O_/W6[ )DJ2P_$!?1]B/4?*ZA?X5C1[<97&(Z.WWQ7,]*\
MB!X,M]Q$[].SL;'H=%;/7F:05PQ G/JI% Q<;)X77T=82W^T"YI;R(]1Y*Z[
M8:Q[@+I*/#=9VM_"$;'Y2TDV%+-+F@G*^'57VY]Z#8,L\IF!.L#A4V,7TJ;=
M,T/5;2HNZP'-'VCX'G8N4>I7-PFKF99;W21M#D%HD!< SB1J.PO:CA?U#%RP
MAAO^YO LW"I,% "H1:P1)HEH,Y#F=SCF5)0;TZXS_)B&$O%><<4?)0P6!\^?
M[_&LP=W/SH8\25:E&R(V^O0.W2GQE0H-9$AR+EOA'82ZBPX5C/F)%Z+035W4
MJ#G(E*^O76]/0VE^(SPL!C!$G34-5RWUNX!'G:  :$HGNF0$53FU0C?*;[QL
MT+SQX9TU5&(D?;LA"=H#;#,VPK8@H573&OJ"#SC/-?,.+NK;KWI/B3(C=1'G
M&:R1O[@FS=@KU6U/)ZJZ1FX#0FX1PC$#L=GI;!0_<H\*R,PYGM5;92:=H&,>
M,M5<.1YIA87@>LD#N<;T@Y6:S AH\XW:2N=CZ;1;J[QVG@T'F9MLCBJOW37!
M67!*[Y.P\.R-# :(9B+)/+!]E85!.S I#??H_0\;\"[/4VY%E(,A2:6S[;'5
MT-L=WDCGU9>,['$%*5S4/2OZ*<T:NBUV)]JW8?[UI5WPF" FRR[HW@\ AGK0
M@#G2QA@0()DM&P+L/:T_#>MCR,4;Y7 777O+"!I(V3]70_$!B3 JB@J,OU<E
M]+(Y1Q_TNV]W1^W6IX9ZS^),#Z9=\]L@'>2-X1CQ:&_U;6U$,BMT9W@2RST.
MS^= /@A'@1=FK:L&A4?!E;60BAH<9)_X]L*M5/3II(H<(J\A%1VS"O%X$4[1
M<'M#9)_R$3W&-KK>R*3.'0^)#62=K@:Z;#LOKV, UT2#1H@D=E1ERC<-AA)#
MR,OLV!1[P,9K ?B 248YC_;%BPB(I?WV_#B%)L*0FUI+V]@5M0'P/%?UG7ST
MR0ZM3+1-JARTPRM^IAYV\Z"<<L+Z H8Z:LB$1D_=) H%4)*N/E;:ABEK)A=?
MZ&7I5J#T)O8HXA7%:N+_@$</;'I/+9Q1%[+=&DW1P^J.N)@=W]F _99X^]=R
MO+,_>/98[#W=[_:?/1W^!JP^Y*W7NUG]\&(B67-_LYSR:2)$DP-NZ:E;_W\.
MTH=UL<-#<<ZO'K@#.O<ROOYQ)AV*ZW<RJVC-?Z?3)3F[3O^D@K#;7]=^P'O>
M.+,A<"WJH;A:ECAZ9(%IDD/Q3N8JJ..=(?F&&RUMO8N^^3P[X%WZVXCPQQ+T
M-Q7_ E!+ P04    " #A@_I4MTV0X]\,   F*@  %@   '1M,C(R,3@S-&0Q
M7V5X.3DM,BYH=&WM6FUO&S<2_BY _X&7%JD-2+*DQ$[]<D:5V$9R<6.?[;37
MC]0N9;'>76Y(KF3UU]\S0ZZTLIW6Z15I@%R1PA*7+_/R<.:961V\OOKQ]+#=
M.GA]/#K"7T'_'5R]N3H]/CS8"G_Q="L^/GAY=O2+N+SZY?3XGT\FIO![8M O
MO;C2N7+BG9J+"Y/+HA,&.N)263UY@H58>EZORZ6]UL6>Z#\Y?%J,7;E_L'5^
M9XI7M[XK,WV-:59?3_V^:*PZ>'EX?#O58^W%[FYO>+#U\O#^%H\XY;$*- ['
MU/Z^:(J7J,(KNR\2DQF[)[X9[@R_'XY8R+?:6"G.I]+F,E&5UXG,G!@5A:F*
M1+EVZU5FG"ZNA9F(;W=Z??&CSC)M"O&^2)6=6^V]*L1Y-<YT(LXF$\B"R;)(
MQ4F59>+X5ME$.T7+SV;*=D=99GP.><19Z;'/PX;Y"[5^G -_K9S7D\6^^-,G
MCV5R<VUAM;0;S3R?:J]@Y).S=U?UF4L/#(;;P]W?674I,]]NG<H;)5YIO^B(
M]UY.N]T-B.,F.L.HL65/=,6_JFPAACL=,>P/AYL8>-"C'?&F2'IBX]WH\FCT
M[SWQ]OSB/YL=L?'T0V7\/B\)'X6QPD^5"-]>F;R4Q2)\V6RWO$GE MX-Z$C%
MP18IMZ[B1U6B;9,5FF0AJB:&RH A4V-H DFPCW.BM"91*G6\JL2W6YU+K[)%
MN\60S ,D.W10,A6Z2+(JA>LFA$#50"!)L#Q3V:???#\<O-C'OH1,N42F860*
M;R"33:82BV6::AJ4F7"P+#8GB,^EM;+PKM-NE5:3Y8Q(55HEGA18GD1?4NT2
MV,2'A8G)<^T<-@S?ETJKVU(53KE>;=F_[FI\U"]?TOWXZ*RKJ6JWEF::2T<V
MA-&=(NN)#;TIAL\Z.[O;^/]%[2,\($O#E\Z;Y 9XUY@WZ R_[S>FD+SX=(RY
M!8#@]1C7J[0*9UGLOEJ*M<_ZG7XX@R*C!#A'XN>( C'7?DJP7D(.\B4,O&_[
MO6%?E,J&8]GG$L'*YO34%$HLE+0P+C X)P4)J;H =&0#P2E W^&U&WKVD"PO
M_W=9)GH6A'&/D:8GX)>X-79LM\*6]^Q^QU1\YAV1V:<LVYU-Q7)/]RA'\;[M
MUNJPYCW>[O3[_8_ XT&I'KV8Q1_0C%X_JE"'AW8+=[V"A!I!9:J=\!AV,N$H
M0[I-]"V>LL8I2Y$:41A/>GJ)10C!8B:MED%AG7!\5-)7=A4JQ-7C;A)=I/D*
M)@B18U5[E0\8*]S;@J-TP:Y7N'80=A9\SE%86 4/P"9!>5=F(#HLJ9 YQ3GA
MJLD$@JIH0\ +,WBW&D"Z:+<X1,?(O(RFK#?.I[5565MX:C+$TY  9I)7N0KA
M_B%)0DQM'B?'&@\6=\]B1T78Q@-RI>CPE6VF*DO)%(CO8X6LI! Q2J_R,28C
MYG#B[8FO)V"?RE05X\I>PW8RPT:%>"KS<A^4I!=H!J!-0 ;PG2% &7/3M57
M%.;+:U@.8(&;"Q5N 8<KOAMUC.]]!9;\A-3G5%(1E<"Q,9A(OV13D?&(9YW=
MX79G>[C]T01X+V<UXUM5TM<_VJ3=XHRQ(D3W<L^G[]FIE>+K3A?T0>ZVSM/
M!YBHA6#;,-!<<;X CBBJ5M95,9)3V+K6#N&70><\PEE@?(4X,4B E]V!V#@A
M>OT.6'[V[%EWN/-\Y_E@L^:6%.53E622ME[&Q79KO& !WR-)XL$E;>R AJ5(
M9++C6Y@$40WWI&9_(.#@H,/^_N7Q*_XTV-\D80*I'\38\O6$EL=>".V(<2O
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MKZ(G?[HN^;BWMNAWGN&'G_3[T/\"4$L! A0#%     @ X8/Z5 +FY Q! P
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M.#,T9#%?.&LN:'1M4$L! A0#%     @ X8/Z5"[RV)GKJ@  >_ # !4
M         ( !NS4  '1M,C(R,3@S-&0Q7V5X,2TQ+FAT;5!+ 0(4 Q0    (
M .&#^E3P6_VD=D8  "F2 0 5              "  =G@  !T;3(R,C$X,S1D
M,5]E>#,M,2YH=&U02P$"% ,4    " #A@_I4,LH0%E]-   "I0$ %0
M        @ &")P$ =&TR,C(Q.#,T9#%?97@T+3,N:'1M4$L! A0#%     @
MX8/Z5'4+\D"A#0  6C$  !8              ( !%'4! '1M,C(R,3@S-&0Q
M7V5X.3DM,2YH=&U02P$"% ,4    " #A@_I4MTV0X]\,   F*@  %@
M        @ 'I@@$ =&TR,C(Q.#,T9#%?97@Y.2TR+FAT;5!+!08     "0 )
+ %8"  #\CP$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
